Peripheral nerves are composed of sensory, motor, and autonomic elements. Diseases can affect the cell body of a neuron or its peripheral processes, namely the axons or the encasing myelin sheaths. Most peripheral nerves are mixed and contain sensory and motor as well as autonomic fibers. Nerves can be subdivided into three major classes: large myelinated, small myelinated, and small unmyelinated. Motor axons are usually large myelinated fibers that conduct rapidly (~50 m/s). Sensory fibers may be any of the three types. Large-diameter sensory fibers conduct proprioception and vibratory sensation to the brain, while the smaller-diameter myelinated and unmyelinated fibers transmit pain and temperature sensation. Autonomic nerves are also small in diameter. Thus, peripheral neuropathies can impair sensory, motor, or autonomic function, either singly or in combination. Peripheral neuropathies are further classified into those that primarily affect the cell body (e.g., neuronopathy or ganglionopathy), myelin (myelinopathy), and the axon (axonopathy). These different classes of peripheral neuropathies have distinct clinical and electrophysiologic features. This chapter discusses the clinical approach to a patient suspected of having a peripheral neuropathy, as well as specific neuropathies, including hereditary and acquired neuropathies. The inflammatory neuropathies are discussed in Chap. 439.
In approaching a patient with a neuropathy, the clinician has three main goals: (1) identify where the lesion is, (2) identify the cause, and (3) determine the proper treatment. The first goal is accomplished by obtaining a thorough history, neurologic examination, and electrodiagnostic and other laboratory studies (Fig. 438-1). While gathering this information, seven key questions are asked (Table 438-1), the answers to which help identify the pattern of involvement and the cause of the neuropathy (Table 438-2). Despite an extensive evaluation, in approximately half of patients no etiology is ever found; these patients typically have a predominately sensory polyneuropathy and have been labeled as having idiopathic or cryptogenic sensory polyneuropathy (CSPN).
Approach to the evaluation of peripheral neuropathies. CIDP, chronic inflammatory demyelinating polyradiculoneuropathy; EDx, electrodiagnostic; GBS, Guillain-Barré syndrome; IVIg, intravenous immunoglobulin.
TABLE 438-1Approach to Neuropathic Disorders: Seven Key Questions ||Download (.pdf) TABLE 438-1 Approach to Neuropathic Disorders: Seven Key Questions
What systems are involved?
What is the distribution of weakness?
What is the nature of the sensory involvement?
Temperature loss or burning or stabbing pain (e.g., small fiber)
Vibratory or proprioceptive loss (e.g., large fiber)
Is there evidence of upper motor neuron involvement?
Without sensory loss
With sensory loss
What is the temporal evolution?
Is there evidence for a hereditary neuropathy?
Are there any associated medical conditions?
Cancer, diabetes mellitus, connective tissue disease or other autoimmune diseases, infection (e.g., HIV, Lyme disease, leprosy)
Medications including over-the-counter drugs that may cause a toxic neuropathy
Preceding events, drugs, toxins
TABLE 438-2Patterns of Neuropathic Disorders ||Download (.pdf) TABLE 438-2 Patterns of Neuropathic Disorders
|Pattern 1: Symmetric proximal and distal weakness with sensory loss |
| Consider: inflammatory demyelinating polyneuropathy (GBS and CIDP) |
|Pattern 2: Symmetric distal sensory loss with or without distal weakness |
| Consider: cryptogenic or idiopathic sensory polyneuropathy (CSPN), diabetes mellitus and other metabolic disorders, drugs, toxins, familial (HSAN), CMT, amyloidosis, and others |
|Pattern 3: Asymmetric distal weakness with sensory loss |
| With involvement of multiple nerves |
| Consider: multifocal CIDP, vasculitis, cryoglobulinemia, amyloidosis, sarcoid, infectious (leprosy, Lyme, hepatitis B, C, or E, HIV, CMV), HNPP, tumor infiltration |
| With involvement of single nerves/regions |
| Consider: may be any of the above but also could be compressive mononeuropathy, plexopathy, or radiculopathy |
|Pattern 4: Asymmetric proximal and distal weakness with sensory loss |
| Consider: polyradiculopathy or plexopathy due to diabetes mellitus, meningeal carcinomatosis or lymphomatosis, sarcoid, amyloid, hereditary plexopathy (HNPP, HNA), idiopathic |
|Pattern 5: Asymmetric distal weakness without sensory loss |
| With upper motor neuron findings |
| Consider: motor neuron disease |
| Without upper motor neuron findings |
| Consider: progressive muscular atrophy, juvenile monomelic amyotrophy (Hirayama’s disease), multifocal motor neuropathy, multifocal acquired motor axonopathy |
|Pattern 6: Symmetric sensory loss and distal areflexia with upper motor neuron findings |
| Consider: Vitamin B12, vitamin E, and copper deficiency with combined system degeneration with peripheral neuropathy, chronic liver disease, hereditary leukodystrophies (e.g., adrenomyeloneuropathy) HSP-plus |
|Pattern 7: Symmetric weakness without sensory loss |
| With proximal and distal weakness |
| Consider: SMA |
| With distal weakness |
| Consider: hereditary motor neuropathy (“distal” SMA) or atypical CMT |
|Pattern 8: Focal midline proximal symmetric weakness |
| Neck extensor weakness |
| Consider: ALS |
| Bulbar weakness |
| Consider: ALS/PLS, isolated bulbar ALS (IBALS), Kennedy’s syndrome (X-linked, bulbospinal SMA), bulbar presentation GBS |
| Diaphragm weakness (SOB) |
| Consider: ALS |
|Pattern 9: Asymmetric proprioceptive sensory loss without weakness |
| Consider causes of a sensory neuronopathy (ganglionopathy): |
| Cancer (paraneoplastic) |
| Sjögren’s syndrome |
| Idiopathic sensory neuronopathy (possible GBS variant) |
| Cisplatin and other chemotherapeutic agents |
| Vitamin B6 toxicity |
| HIV-related sensory neuronopathy |
|Pattern 10: Autonomic symptoms and signs |
| Consider neuropathies associated with prominent autonomic dysfunction: |
| Hereditary sensory and autonomic neuropathy |
| Amyloidosis (familial and acquired) |
| Diabetes mellitus |
| Idiopathic pandysautonomia (may be a variant of Guillain-Barré syndrome) |
| Porphyria |
| HIV-related autonomic neuropathy |
| Vincristine and other chemotherapeutic agents |
INFORMATION FROM THE HISTORY AND PHYSICAL EXAMINATION: SEVEN KEY QUESTIONS
1. What Systems Are Involved?
It is important to determine if the patient’s symptoms and signs are motor, sensory, autonomic, or a combination of these. If the patient has only weakness without any evidence of sensory or autonomic dysfunction, a motor neuropathy, neuromuscular junction abnormality, or myopathy should be considered. Some peripheral neuropathies are associated with significant autonomic nervous system dysfunction. Symptoms of autonomic involvement include fainting spells or orthostatic lightheadedness; heat intolerance; or any bowel, bladder, or sexual dysfunction (Chap. 432). There will typically be an orthostatic fall in blood pressure without an appropriate increase in heart rate. Autonomic dysfunction in the absence of diabetes should alert the clinician to the possibility of amyloid polyneuropathy. Rarely, a pandysautonomic syndrome can be the only manifestation of a peripheral neuropathy without other motor or sensory findings. The majority of neuropathies are predominantly sensory in nature.
2. What Is the Distribution of Weakness?
Delineating the pattern of weakness, if present, is essential for diagnosis, and in this regard two additional questions should be answered: (1) Does the weakness only involve the distal extremity, or is it both proximal and distal? and (2) Is the weakness focal and asymmetric, or is it symmetric? Symmetric proximal and distal weakness is the hallmark of acquired immune demyelinating polyneuropathies, both the acute form (Guillain-Barré syndrome [GBS]) and the chronic form (chronic inflammatory demyelinating polyneuropathy [CIDP]) (Chap. 439). The importance of finding symmetric proximal and distal weakness in a patient who presents with both motor and sensory symptoms cannot be overemphasized because this identifies the important subset of patients who may have a treatable acquired demyelinating neuropathic disorder (i.e., GBS or CIDP).
Findings of an asymmetric or multifocal pattern of weakness narrow the differential diagnosis. Some neuropathic disorders may present with unilateral extremity weakness. In the absence of sensory symptoms and signs, such weakness evolving over weeks or months would be worrisome for motor neuron disease (e.g., amyotrophic lateral sclerosis [ALS]), but it would be important to exclude multifocal motor neuropathy that may be treatable (Chap. 439). In a patient presenting with asymmetric subacute or acute sensory and motor symptoms and signs, radiculopathies, plexopathies, compressive mononeuropathies, or multiple mononeuropathies (e.g., mononeuropathy multiplex) must be considered.
ALS can produce prominent neck extensor weakness (head drop), tongue and pharyngeal weakness (dysarthia and dysphagia), or shortness of breath. These focal symmetric weakness patterns can also be seen in neuromuscular junction disorders (myasthenia gravis, Lambert-Eaton myasthenic syndrome [LEMS] [Chap. 440]) and some myopathies, particularly isolated neck extensor myopathy (Chap. 441).
3. What Is the Nature of the Sensory Involvement?
The patient may have loss of sensation (numbness), altered sensation to touch (hyperpathia or allodynia), or uncomfortable spontaneous sensations (tingling, burning, or aching) (Chap. 22). Neuropathic pain can be burning, dull, and poorly localized (protopathic pain), presumably transmitted by polymodal C nociceptor fibers, or sharp and lancinating (epicritic pain), relayed by A-delta fibers. If pain and temperature perception are lost, while vibratory and position sense are preserved along with muscle strength, deep tendon reflexes, and normal nerve conduction studies (NCS), a small-fiber neuropathy is likely. This is important, because the most likely cause of small-fiber neuropathies, when one is identified, is diabetes mellitus (DM) or glucose intolerance. Amyloid neuropathy should be considered as well in such cases, but most of these small-fiber neuropathies remain idiopathic despite extensive evaluation.
Severe proprioceptive loss also narrows the differential diagnosis. Affected patients will note imbalance, especially in the dark. A neurologic examination revealing a dramatic loss of proprioception with vibration loss and normal strength should alert the clinician to consider a sensory neuronopathy/ganglionopathy (Table 438-2, Pattern 9). In particular, if this loss is asymmetric or affects the arms more than the legs, this pattern suggests a non-length-dependent process as seen in sensory neuronopathies.
4. Is There Evidence of Upper Motor Neuron Involvement?
If the patient presents with symmetric distal sensory symptoms and signs suggestive of a distal sensory neuropathy, but there is additional evidence of symmetric upper motor neuron involvement (Chap. 21), the physician should consider a combined system degeneration with neuropathy. The most common cause for this pattern is vitamin B12 deficiency, but other etiologies should also be considered (e.g., copper deficiency, human immunodeficiency virus [HIV] infection, severe hepatic disease, adrenomyeloneuropathy [AMN]), and hereditary spastic paraplegia plus a neuropathy.
5. What Is the Temporal Evolution?
It is important to determine the onset, duration, and evolution of symptoms and signs. Does the disease have an acute (days to 4 weeks), subacute (4–8 weeks), or chronic (>8 weeks) course? Is the course monophasic, progressive, or relapsing? Most neuropathies are insidious and slowly progressive in nature. Neuropathies with acute and subacute presentations include GBS, vasculitis, and radiculopathies related to diabetes or Lyme disease. A relapsing course can be present in CIDP and porphyria.
6. Is There Evidence for a Hereditary Neuropathy?
In patients with slowly progressive distal weakness over many years with few sensory symptoms yet significant sensory deficits on clinical examination, the clinician should consider a hereditary neuropathy (e.g., Charcot-Marie-Tooth disease [CMT]). On examination, the feet may show high or flat arches or hammer toes, and scoliosis may be present. In suspected cases, it may be necessary to perform neurologic and electrophysiologic studies on family members in addition to the patient.
7. Does the Patient Have Any Other Medical Conditions?
It is important to inquire about associated medical conditions (e.g., DM, systemic lupus erythematosus [SLE]); preceding or concurrent infections (e.g. diarrheal illness preceding GBS); surgeries (e.g., gastric bypass and nutritional neuropathies); medications (toxic neuropathy), including over-the-counter vitamin preparations (B6); alcohol; dietary habits; and use of dentures (e.g., fixatives contain zinc that can lead to copper deficiency).
PATTERN RECOGNITION APPROACH TO NEUROPATHIC DISORDERS
Based on the answers to the seven key questions, neuropathic disorders can be classified into several patterns based on the distribution or pattern of sensory, motor, and autonomic involvement (Table 438-2). Each pattern has a limited differential diagnosis, and information from laboratory studies usually permits a final diagnosis to be established.
The electrodiagnostic (EDx) evaluation of patients with a suspected peripheral neuropathy consists of NCS and needle electromyography (EMG). In addition, studies of autonomic function can be valuable. The electrophysiologic data can confirm whether the neuropathic disorder is a mononeuropathy, multiple mononeuropathy (mononeuropathy multiplex), radiculopathy, plexopathy, or generalized polyneuropathy. Similarly, EDx evaluation can ascertain whether the process involves only sensory fibers, motor fibers, autonomic fibers, or a combination of these. Finally, the electrophysiologic data can help distinguish axonopathies from myelinopathies as well as axonal degeneration secondary to ganglionopathies from the more common length-dependent axonopathies.
NCS are most helpful in classifying a neuropathy as due to axonal degeneration or segmental demyelination (Table 438-3). In general, low-amplitude potentials with relatively preserved distal latencies, conduction velocities, and late potentials, along with fibrillations on needle EMG, suggest an axonal neuropathy. On the other hand, slow conduction velocities, prolonged distal latencies and late potentials, relatively preserved amplitudes, and the absence of fibrillations on needle EMG imply a primary demyelinating neuropathy. The presence of nonuniform slowing of conduction velocity, conduction block, or temporal dispersion further suggests an acquired demyelinating neuropathy (e.g., GBS or CIDP) as opposed to a hereditary demyelinating neuropathy (e.g., CMT type 1).
TABLE 438-3Electrophysiologic Features: Axonal Degeneration versus Segmental Demyelination ||Download (.pdf) TABLE 438-3 Electrophysiologic Features: Axonal Degeneration versus Segmental Demyelination
| ||Axonal Degeneration ||Segmental Demyelination |
|Motor Nerve Conduction Studies |
|CMAP amplitude ||Decreased ||Normal (except with CB or distal dispersion) |
|Distal latency ||Normal ||Prolonged |
|Conduction velocity ||Normal ||Slow |
|Conduction block ||Absent ||Present |
|Temporal dispersion ||Absent ||Present |
|F wave ||Normal or absent ||Prolonged or absent |
|H reflex ||Normal or absent ||Prolonged or absent |
|Sensory Nerve Conduction Studies |
|SNAP amplitude ||Decreased ||Normal or decreased |
|Distal latency ||Normal ||Prolonged |
|Conduction velocity ||Normal ||Slow |
|Needle EMG |
|Spontaneous activity |
| Fibrillations ||Present ||Absent |
| Fasciculations ||Present ||Absent |
|Motor unit potentials || || |
| Recruitment ||Decreased ||Decreased |
| Morphology ||Long duration, large amplitude, polyphasic (if there is reinnervation) ||Normal |
Autonomic studies are used to assess small myelinated (A-delta) or unmyelinated (C) nerve fiber involvement. Such testing includes heart rate response to deep breathing, heart rate, and blood pressure response to both the Valsalva maneuver and tilt-table testing and quantitative sudomotor axon reflex testing (Chap. 432). These studies are particularly useful in patients who have pure small-fiber neuropathy or autonomic neuropathy in which routine NCS are normal. A number of novel autoantibodies have recently been found in patients with small fiber neuropathy which may have both diagnostic and treatment implications in the future.
OTHER IMPORTANT LABORATORY INFORMATION
In patients with generalized symmetric peripheral neuropathy, a standard laboratory evaluation should include a complete blood count, basic chemistries including serum electrolytes and tests of renal and hepatic function, fasting blood glucose (FBS), hemaglobin (Hb) A1c, urinalysis, thyroid function tests, B12, folate, erythrocyte sedimentation rate (ESR), rheumatoid factor, antinuclear antibodies (ANA), serum protein electrophoresis (SPEP) and immunoelectrophoresis or immunofixation, and urine for Bence Jones protein. Quantification of the concentration of serum-free light chains and the kappa/lambda ratio is more sensitive than SPEP, immunoelectrophoresis, or immunofixation to detect a monoclonal gammopathy and therefore should be done if amyloidosis is suspected. A skeletal survey should be performed in patients with acquired demyelinating neuropathies and M-spikes to look for osteosclerotic or lytic lesions. Patients with monoclonal gammopathy should also be referred to a hematologist for consideration of a bone marrow biopsy. An oral glucose tolerance test is indicated in patients with painful sensory neuropathies even if FBS and HbA1c are normal, as the test is abnormal in about one-third of such patients. In addition to the above tests, patients with a mononeuropathy multiplex pattern of involvement should have a vasculitis workup, including antineutrophil cytoplasmic antibodies (ANCA), cryoglobulins, hepatitis serology, Western blot for Lyme disease, HIV, and occasionally a cytomegalovirus (CMV) titer.
There are many autoantibody panels (various antiganglioside antibodies) marketed for screening routine neuropathy patients for a treatable condition. These autoantibodies have no proven clinical utility or added benefit beyond the information obtained from a complete clinical examination and detailed EDx. A heavy metal screen is also not necessary as a screening procedure, unless there is a history of possible exposure or suggestive features on examination (e.g., severe painful sensorimotor and autonomic neuropathy and alopecia—thallium; severe painful sensorimotor neuropathy with or without gastrointestinal [GI] disturbance and Mee’s lines—arsenic; wrist or finger extensor weakness and anemia with basophilic stippling of red blood cells—lead).
In patients with suspected GBS or CIDP, a lumbar puncture is indicated to look for an elevated cerebrospinal fluid (CSF) protein. In idiopathic cases of GBS and CIDP, CSF pleocytosis is usually absent. If cells are present, one should consider HIV infection, Lyme disease, sarcoidosis, or lymphomatous or leukemic infiltration of nerve roots. Some patients with GBS and CIDP have abnormal liver function tests. In these cases, it is important to also check for hepatitis B and C, HIV, CMV, and Epstein-Barr virus (EBV) infection. In patients with an axonal GBS (by EMG/NCS) or those with a suspicious coinciding history (e.g., unexplained abdominal pain, psychiatric illness, significant autonomic dysfunction), it is reasonable to screen for porphyria.
In patients with a severe sensory ataxia, a sensory ganglionopathy or neuronopathy should be considered. The most common causes of sensory ganglionopathies are Sjögren’s syndrome (Chap. 354) and a paraneoplastic neuropathy (Chap. 90). Neuropathy can be the initial manifestation of Sjögren’s syndrome. Thus, one should always inquire about dry eyes and mouth in patients with sensory signs and symptoms. Further, some patients can manifest sicca complex without other manifestations of Sjögren’s syndrome. Thus, patients with sensory ataxia should be tested for antibodies to SS-A/Ro and SS-B/La, in addition to the routine ANA. To evaluate a possible paraneoplastic sensory ganglionopathy, antineuronal nuclear antibodies (e.g., anti-Hu antibodies) should be obtained. These antibodies are most commonly seen in patients with small-cell carcinoma of the lung but are also present with breast, ovarian, lymphoma, and other cancers. Importantly, the paraneoplastic neuropathy can precede the detection of the cancer, and detection of these autoantibodies should lead to a search for malignancy.
Nerve biopsies are now rarely performed in the evaluation of neuropathies. The primary indication for nerve biopsy is suspicion for amyloid neuropathy or vasculitis. In most instances, the abnormalities present on biopsies do not help distinguish one form of peripheral neuropathy from another (beyond what is already apparent by clinical examination and the NCS). Nerve biopsies should only be performed when the NCS are abnormal. The sural nerve is most commonly biopsied because it is a pure sensory nerve and biopsy will not result in loss of motor function. In suspected vasculitis, a combination biopsy of a superficial peroneal nerve (pure sensory) and the underlying peroneus brevis muscle obtained from a single small incision increases the diagnostic yield. Tissue can be analyzed to assess for evidence of inflammation, vasculitis, or amyloid deposition. Semithin plastic sections, teased fiber preparations, and electron microscopy are used to assess the morphology of the nerve fibers and to distinguish axonopathies from myelinopathies.
Skin biopsies are sometimes used to diagnose a small-fiber neuropathy. Following a punch biopsy of the skin in the distal lower extremity, immunologic staining can be used to measure the density of small unmyelinated fibers. The density of these nerve fibers is reduced in patients with small-fiber neuropathies in whom NCS and routine nerve biopsies are often normal. This technique may allow for an objective measurement in patients with mainly subjective symptoms. However, it often adds little to what one already knows from the clinical examination and EDx.
CMT disease is the most common type of hereditary neuropathy (Pattern 2, Table 438-2). Rather than one disease, CMT is a syndrome of many genetically distinct disorders (Table 438-4). The various subtypes of CMT are classified according to the nerve conduction velocities (NCVs) and predominant pathology (e.g., demyelination or axonal degeneration), inheritance pattern (autosomal dominant, recessive, or X-linked), and the specific mutated genes. Type 1 CMT (or CMT1) refers to inherited demyelinating sensorimotor neuropathies, whereas the axonal sensory neuropathies are classified as CMT2. By definition, motor conduction velocities in the arms are slowed to <38 m/s in CMT1 and are >38 m/s in CMT2. However, most cases of CMT1 actually have motor NCVs between 20 and 25 m/s. CMT1 and CMT2 usually begin in childhood or early adult life; however, onset later in life can occur, particularly in CMT2. Both are inherited in an autosomal dominant fashion, with a few exceptions. CMT3 is an autosomal dominant neuropathy that appears in infancy and is associated with severe demyelination or hypomyelination. CMT4 is an autosomal recessive neuropathy that typically begins in childhood or early adult life. There are no medical therapies for any of the CMTs, but physical and occupational therapy can be beneficial, as can bracing (e.g., ankle-foot orthotics for footdrop) and other orthotic devices.
TABLE 438-4Classification of Charcot-Marie-Tooth Disease and Related Neuropathies ||Download (.pdf) TABLE 438-4 Classification of Charcot-Marie-Tooth Disease and Related Neuropathies
|Name ||Inheritance ||Gene Location ||Gene Product |
|CMT1 || || || |
| CMT1A ||AD ||17p11.2 ||PMP-22 (usually duplication of gene) |
| CMT1B ||AD ||1q21-23 ||MPZ |
| CMT1C ||AD ||16p13.1-p12.3 ||LITAF |
| CMT1D ||AD ||10q21.1-22.1 ||ERG2 |
| CMT1E (with deafness) ||AD ||17p11.2 ||Point mutations in PMP 22 gene |
| CMT1F ||AD ||8p13-21 ||Neurofilament light chain |
| CMT1G ||AD ||14q32.33 ||INF2 |
| CMT1X ||X-linked dominant ||Xq13 ||Connexin-32 |
|HNPP ||AD ||17p11.2 ||PMP-22 |
| || ||1q21-23 ||MPZ |
|CMT dominant-intermediate (CMTD1) || || || |
| CMTD1A ||AD ||10q24.1-25.1 ||? |
| CMTD1B ||AD ||19.p12-13.2 ||Dynamin 2 |
| CMTD1C ||AD ||1p35 ||YARS |
| CMTD1D ||AD ||1q22 ||MPZ |
|CMT2 || || || |
| CMT2A2 (allelic to HMSN VI with optic atrophy) ||AD ||1p36.2 ||MFN2 |
| CMT2B ||AD ||3q13-q22 ||RAB7 |
| CMT2B1 (allelic to LGMD 1B) ||AR ||1q21.2 ||Lamin A/C |
| CMT2B2 ||AR and AD ||19q13 ||MED25 for AR; Unknown for AD |
| CMT2C (with vocal cord and diaphragm paralysis) ||AD ||12q23-24 ||TRPV4 |
| CMT2D (allelic to distal SMA5) ||AD ||7p14 ||Glycine tRNA synthetase |
| CMT2E (allelic to CMT 1F) ||AD ||8p21 ||Neurofilament light chain |
| CMT2F ||AD ||7q11-q21 ||Heat-shock 27-kDa protein-1 |
| CMT2G ||AD ||9q31.3-34.2 ||LRSAM1 |
| CMT2I (allelic to CMT1B) ||AD ||1q22 ||MPZ |
| CMT2J ||AD ||1q22 ||MPZ |
| CMT2H, CMT2K (allelic to CMT4A) ||AD ||8q13-q21 ||GDAP1 |
| CMT2L (allelic to distal hereditary motor neuropathy type 2) ||AD ||12q24 ||Heat-shock protein 8 |
| CMT2M ||AD ||16q22 ||Dynamin-2 |
| CMT2N ||AD ||16q22.1 ||AARS |
| CMT2O ||AD ||14q32.31 ||DYNC1H1 |
| CMT2P ||AD ||9q31.3-34.2 ||LRSAM1 |
| CMT2P-Okinawa (HSMN2P) ||AD ||3q13-q14 ||TFG |
| CMT2X ||X-linked ||Xq22-24 ||PRPS1 |
|CMT3 ||AD ||17p11.2 ||PMP-22 |
| (Dejerine-Sottas disease, congenital hypomyelinating neuropathy) ||AD ||1q21-23 ||MPZ |
| ||AR ||10q21.1-22.1 ||ERG2 |
| ||AR ||19q13 ||Periaxon |
|CMT4 || || || |
| CMT4A ||AR ||8q13-21.1 ||GDAP1 |
| CMT4B1 ||AR ||11q23 ||MTMR2 |
| CMT4B2 ||AR ||11p15 ||MTMR13 |
| CMT4C ||AR ||5q23-33 ||SH3TC2 |
| CMT4D (HMSN-Lom) ||AR ||8q24 ||NDRG1 |
| CMT4E (congenital hypomyelinating neuropathy) ||AR ||Multiple ||Includes PMP22, MPZ, and ERG-2 |
| CMT4F ||AR ||19q13.1-13.3 ||Periaxin |
| CMT4G ||AR ||10q23.2 ||HK1 |
| CMT4H ||AR ||12q12-q13 ||Frabin |
| CMT4J ||AR ||6q21 ||FIG4 |
|HNA ||AD ||17q24 ||SEPT9 |
|HSAN1A ||AD ||9q22 ||SPTLC1 |
|HSAN1B ||AD ||3q21 ||RAB7 |
|HSAN1C ||AD ||14q24.3 ||SPTLC2 |
|HSAN1D ||AD ||14q21.3 ||ATL1 |
|HSAN1E ||AD ||19p13.2 ||DNMT1 |
|HSAN2A ||AR ||12p13.33 ||PRKWNK1 |
|HSAN2B ||AR ||5p15.1 ||FAM134B |
|HSAN2C ||AR ||12q13.13 ||KIF1A |
|HSAN2D ||AR ||2q24.3 ||SCN9A |
|HSAN3A ||AR ||9q21 ||IKAP |
|HSAN3B ||AR ||6p12.1 ||Dystonin |
|HSAN4 ||AR ||3q ||trkA/NGF receptor |
|HSAN5 ||AD or AR ||1p11.2-p13.2 ||NGFb |
| || ||2q24.3 ||SCN9A |
| || ||3p22.2 ||SCN11A |
|HSAN6 ||AR ||6p12.1 ||Dystonin |
CMT1 is the most common form of hereditary neuropathy. Affected individuals usually present in the first to third decade of life with distal leg weakness (e.g., foot drop), although patients may remain asymptomatic even late in life. People with CMT generally do not complain of numbness or tingling, which can be helpful in distinguishing CMT from acquired forms of neuropathy in which sensory symptoms usually predominate. Although usually asymptomatic, reduced sensation to all modalities is apparent on examination. Muscle stretch reflexes are unobtainable or reduced throughout. There is often atrophy of the muscles below the knee (particularly the anterior compartment), leading to so-called inverted champagne bottle legs.
Motor NCVs are generally in the 20–25 m/s range. Nerve biopsies usually are not performed on patients suspected of having CMT1, because the diagnosis usually can be made by less invasive testing (e.g., NCS and genetic studies). However, when done, the biopsies reveal reduced numbers of myelinated nerve fibers with a predilection for loss of large-diameter fibers and Schwann cell proliferation around thinly or demyelinated fibers, forming so-called onion bulbs.
CMT1A is the most common subtype of CMT1, representing 70% of cases, and is caused by a 1.5-megabase (Mb) duplication within chromosome 17p11.2-12 encoding the gene for peripheral myelin protein-22 (PMP-22). This results in patients having three copies of the PMP-22 gene rather than two. This protein accounts for 2–5% of myelin protein and is expressed in compact regions of the peripheral myelin sheath. Approximately 20% of patients with CMT1 have CMT1B, caused by mutations in the myelin protein zero (MPZ). CMT1B is for the most part clinically, electrophysiologically, and histologically indistinguishable from CMT1A. MPZ is an integral myelin protein and accounts for more than half of the myelin protein in peripheral nerves. Other forms of CMT1 are much less common and also indistinguishable from one another clinically and electrophysiologically.
CMT2 occurs approximately half as frequently as CMT1 and CMT2 tends to present later in life. Affected individuals usually become symptomatic in the second decade; some cases present earlier in childhood, whereas others remain asymptomatic into late adult life. Clinically, CMT2 is for the most part indistinguishable from CMT1. NCS are helpful in this regard; in contrast to CMT1, the velocities are normal or only slightly slowed. The most common cause of CMT2 is a mutation in the gene for mitofusin 2 (MFN2), which accounts for approximately 20–30% of CMT2 cases overall. MFN2 localizes to the outer mitochondrial membrane, where it regulates the mitochondrial network architecture by participating in mitochondrial fusion. The other genes associated with CMT2 are much less common.
In dominant-intermediate CMTs (CMTDIs), the NCVs are faster than usually seen in CMT1 (e.g., >38 m/s) but slower than in CMT2.
CMT3 was originally described by Dejerine and Sottas as a hereditary demyelinating sensorimotor polyneuropathy presenting in infancy or early childhood. Affected children are severely weak. Motor NCVs are markedly slowed, typically ≤5–10 m/s. Most cases of CMT3 are caused by point mutations in the genes for PMP-22, MPZ, or ERG-2, which are also the genes responsible for CMT1.
CMT4 is extremely rare and is characterized by a severe, childhood-onset sensorimotor polyneuropathy that is usually inherited in an autosomal recessive fashion. Electrophysiologic and histologic evaluations can show demyelinating or axonal features. CMT4 is genetically heterogeneous (Table 438-4).
CMT1X is an X-linked dominant disorder with clinical features similar to CMT1 and CMT2, except that the neuropathy is much more severe in males than in females. CMT1X accounts for ~10–15% of CMT overall. Males usually present in the first two decades of life with atrophy and weakness of the distal arms and legs, areflexia, pes cavus, and hammer toes. Obligate female carriers are frequently asymptomatic, but can develop signs and symptoms of CMT. Onset in females is usually after the second decade of life, and the neuropathy is milder in severity.
NCS reveal features of both demyelination and axonal degeneration. In males, motor NCVs in the arms and legs are moderately slowed (in the low to mid 30-m/s range). About 50% of males with CMT1X have motor NCVs between 15 and 35 m/s with about 80% of these falling between 25 and 35 m/s (intermediate slowing). In contrast, about 80% of females with CMT1X have NCVs in the normal range and 20% have NCVs in the intermediate range. CMT1X is caused by mutations in the connexin 32 gene. Connexins are gap junction structural proteins that are important in cell-to-cell communication.
Hereditary Neuropathy with Liability to Pressure Palsies (HNPP)
HNPP is an autosomal dominant disorder related to CMT1A. While CMT1A is usually associated with a 1.5-Mb duplication in chromosome 17p11.2 that results in an extra copy of PMP-22 gene, HNPP is caused by inheritance of the chromosome with the corresponding 1.5-Mb deletion of this segment, and thus affected individuals have only one copy of the PMP-22 gene. Patients usually manifest in the second or third decade of life with painless numbness and weakness in the distribution of single peripheral nerves, although multiple mononeuropathies can occur (Pattern 3, Table 438-2). Symptomatic mononeuropathy or multiple mononeuropathies are often precipitated by trivial compression of nerve(s) as can occur with wearing a backpack, leaning on the elbows, or crossing one’s legs for even a short period of time. These pressure-related mononeuropathies may take weeks or months to resolve. In addition, some affected individuals manifest with a progressive or relapsing, generalized and symmetric, sensorimotor peripheral neuropathy that resembles CMT.
Hereditary Neuralgic Amyotrophy (HNA)
HNA is an autosomal dominant disorder characterized by recurrent attacks of pain, weakness, and sensory loss in the distribution of the brachial plexus often beginning in childhood (Pattern 4, Table 438-2). These attacks are similar to those seen with idiopathic brachial plexitis (see below). Attacks may occur in the postpartum period, following surgery, or at other times of stress. Most patients recover over several weeks or months. Slightly dysmorphic features, including hypotelorism, epicanthal folds, cleft palate, syndactyly, micrognathia, and facial asymmetry, are evident in some individuals. EDx demonstrate an axonal process. HNA is genetically heterogeneous but can be caused by mutations in septin 9 (SEPT9). Septins may be important in formation of the neuronal cytoskeleton and have a role in cell division, but it is not known how mutations in SEPT9 lead to HNA.
Hereditary Sensory and Autonomic Neuropathy (HSAN)
The HSANs are a very rare group of hereditary neuropathies in which sensory and autonomic dysfunction predominates over muscle weakness, unlike CMT, in which motor findings are most prominent (Pattern 2, Table 438-2; Table 438-4). Nevertheless, affected individuals can develop motor weakness and there can be overlap with CMT. There are no medical therapies available to treat these neuropathies, other than prevention and treatment of mutilating skin and bone lesions.
Of the HSANs, only HSAN1 typically presents in adults. HSAN1 is the most common of the HSANs and is inherited in an autosomal dominant fashion. Affected individuals usually manifest in the second through fourth decades of life. HSAN1 is associated with the degeneration of small myelinated and unmyelinated nerve fibers leading to severe loss of pain and temperature sensation, deep dermal ulcerations, recurrent osteomyelitis, Charcot joints, bone loss, gross foot and hand deformities, and amputated digits. Although most people with HSAN1 do not complain of numbness, they often describe burning, aching, or lancinating pains. Autonomic neuropathy is not a prominent feature, but bladder dysfunction and reduced sweating in the feet may occur. HSAN1A, which is most common, is caused by mutations in the serine palmitoyltransferase long-chain base 1 (SPTLC1) gene.
OTHER HEREDITARY NEUROPATHIES
TABLE 438-5Rare Hereditary Neuropathies ||Download (.pdf) TABLE 438-5 Rare Hereditary Neuropathies
|Hereditary Disorders of Lipid Metabolism |
|Metachromatic leukodystrophy |
|Krabbe’s disease (globoid cell leukodystrophy) |
|Fabry’s disease |
|Refsum’s disease |
|Tangier disease |
|Cerebrotendinous xanthomatosis |
|Hereditary Ataxias with Neuropathy |
|Friedreich’s ataxia |
|Vitamin E deficiency |
|Spinocerebellar ataxia |
|Abetalipoproteinemia (Bassen-Kornzweig disease) |
|Disorders of Defective DNA Repair |
|Cockayne’s syndrome |
|Giant Axonal Neuropathy |
|Acute intermittent porphyria (AIP) |
|Hereditary coproporphyria (HCP) |
|Variegate porphyria (VP) |
|Familial Amyloid Polyneuropathy (FAP) |
|Apolipoprotein A1-related |
Fabry’s disease (angiokeratoma corporis diffusum) is an X-linked dominant disorder. Although men are more commonly and severely affected, women can also manifest symptoms and signs of the disease. Angiokeratomas are reddish-purple maculopapular lesions that are usually found around the umbilicus, scrotum, inguinal region, and perineum. Burning or lancinating pain in the hands and feet often develops in males in late childhood or early adult life (Pattern 2, Table 438-2). However, the neuropathy is usually overshadowed by complications arising from an associated premature atherosclerosis (e.g., hypertension, renal failure, cardiac disease, and stroke) that often lead to death by the fifth decade of life. Some patients also manifest primarily with a dilated cardiomyopathy.
Fabry’s disease is caused by mutations in the a-galactosidase gene that leads to the accumulation of ceramide trihexoside in nerves and blood vessels. A decrease in a-galactosidase activity is evident in leukocytes and cultured fibroblasts. Glycolipid granules may be appreciated in ganglion cells of the peripheral and sympathetic nervous systems and in perineurial cells. Enzyme replacement therapy with a-galactosidase B can improve the neuropathy if patients are treated early, before irreversible nerve fiber loss develops.
Adrenoleukodystrophy (ALD) and AMN are allelic X-linked dominant disorders caused by mutations in the peroxisomal transmembrane adenosine triphosphate-binding cassette (ABC) transporter gene. Patients with ALD manifest with central nervous system (CNS) abnormalities. However, ~30% of patients with mutations in this gene present with the AMN phenotype that typically manifests in the third to fifth decade of life as mild to moderate peripheral neuropathy combined with progressive spastic paraplegia (Pattern 6, Table 438-2) (Chap. 434). Rare patients present with an adult-onset spinocerebellar ataxia or only with adrenal insufficiency.
EDx is suggestive of a primary axonopathy with secondary demyelination. Nerve biopsies demonstrate a loss of myelinated and unmyelinated nerve fibers with lamellar inclusions in the cytoplasm of Schwann cells. Very long chain fatty acid (VLCFA) levels (C24, C25, and C26) are increased in the urine. Laboratory evidence of adrenal insufficiency is evident in approximately two-thirds of patients. The diagnosis can be confirmed by genetic testing.
Adrenal insufficiency is managed by replacement therapy; however, there is no proven effective therapy for the neurologic manifestations of ALD/AMN. Diets low in VLCFAs and supplemented with Lorenzo’s oil (erucic and oleic acids) reduce the levels of VLCFAs and increase the levels of C22 in serum, fibroblasts, and liver; however, several large, open-label trials of Lorenzo’s oil failed to demonstrate efficacy.
Refsum’s disease can manifest in infancy to early adulthood with the classic tetrad of (1) peripheral neuropathy, (2) retinitis pigmentosa, (3) cerebellar ataxia, and (4) elevated CSF protein concentration. Most affected individuals develop progressive distal sensory loss and weakness in the legs leading to foot drop by their 20 s (Pattern 2, Table 438-2). Subsequently, the proximal leg and arm muscles may become weak. Patients may also develop sensorineural hearing loss, cardiac conduction abnormalities, ichthyosis, and anosmia.
Serum phytanic acid levels are elevated. Sensory and motor NCS reveal reduced amplitudes, prolonged latencies, and slowed conduction velocities. Nerve biopsy demonstrates a loss of myelinated nerve fibers, with remaining axons often thinly myelinated and associated with onion bulb formation.
Refsum’s disease is genetically heterogeneous but autosomal recessive in nature. Classical Refsum’s disease with childhood or early adult onset is caused by mutations in the gene that encodes for phytanoyl-CoA α-hydroxylase (PAHX). Less commonly, mutations in the gene encoding peroxin 7 receptor protein (PRX7) are responsible. These mutations lead to the accumulation of phytanic acid in the central and peripheral nervous systems. Treatment is removal of phytanic precursors (phytols: fish oils, dairy products, and ruminant fats) from the diet.
Tangier disease is a rare autosomal recessive disorder that can present as (1) asymmetric multiple mononeuropathies, (2) a slowly progressive symmetric polyneuropathy predominantly in the legs, or (3) a pseudo-syringomyelia pattern with dissociated sensory loss (i.e., abnormal pain/temperature perception but preserved position/vibration in the arms [Chap. 434]). The tonsils may appear swollen and yellowish-orange in color, and there may also be splenomegaly and lymphadenopathy.
Tangier disease is caused by mutations in the ATP-binding cassette transporter 1 (ABC1) gene, which leads to markedly reduced levels of high-density lipoprotein (HDL) cholesterol levels, whereas triacylglycerol levels are increased. Nerve biopsies reveal axonal degeneration with demyelination and remyelination. Electron microscopy demonstrates abnormal accumulation of lipid in Schwann cells, particularly those encompassing umyelinated and small myelinated nerves. There is no specific treatment.
Porphyria is a group of inherited disorders caused by defects in heme biosynthesis (Chap. 409). Three forms of porphyria are associated with peripheral neuropathy: acute intermittent porphyria (AIP), hereditary coproporphyria (HCP), and variegate porphyria (VP). The acute neurologic manifestations are similar in each, with the exception that a photosensitive rash is seen with HCP and VP but not in AIP. Attacks of porphyria can be precipitated by certain drugs (usually those metabolized by the P450 system), hormonal changes (e.g., pregnancy, menstrual cycle), and dietary restrictions.
An acute attack of porphyria may begin with sharp abdominal pain. Subsequently, patients may develop agitation, hallucinations, or seizures. Several days later, back and extremity pain followed by weakness ensues, mimicking GBS (Pattern 1, Table 438-2). Weakness can involve the arms or the legs and can be asymmetric, proximal, or distal in distribution, as well as affecting the face and bulbar musculature. Dysautonomia and signs of sympathetic overactivity are common (e.g., pupillary dilation, tachycardia, and hypertension). Constipation, urinary retention, and incontinence can also be seen.
The CSF protein is typically normal or mildly elevated. Liver function tests and hematologic parameters are usually normal. Some patients are hyponatremic due to inappropriate secretion of antidiuretic hormone (Chap. 371). The urine may appear brownish in color secondary to the high concentration of porphyrin metabolites. Accumulation of intermediary precursors of heme (i.e., d-aminolevulinic acid, porphobilinogen, uroporphobilinogen, coproporphyrinogen, and protoporphyrinogen) is found in urine. Specific enzyme activities can also be measured in erythrocytes and leukocytes. The primary abnormalities on EDx are marked reductions in compound motor action potential (CMAP) amplitudes and signs of active axonal degeneration on needle EMG.
The porphyrias are inherited in an autosomal dominant fashion. AIP is associated with porphobilinogen deaminase deficiency, HCP is caused by defects in coproporphyrin oxidase, and VP is associated with protoporphyrinogen oxidase deficiency. The pathogenesis of the neuropathy is not completely understood. Treatment with glucose and hematin may reduce the accumulation of heme precursors. Intravenous glucose is started at a rate of 10–20 g/h. If there is no improvement within 24 h, intravenous hematin 2–5 mg/kg per day for 3–14 days should be administered.
FAMILIAL AMYLOID POLYNEUROPATHY
Familial amyloid polyneuropathy (FAP) is phenotypically and genetically heterogeneous and is caused by mutations in the genes for transthyretin (TTR), apolipoprotein A1, or gelsolin (Chap. 108). The majority of patients with FAP have mutations in the TTR gene. Amyloid deposition may be evident in abdominal fat pad, rectal, or nerve biopsies. The clinical features, histopathology, and EDx reveal abnormalities consistent with a generalized or multifocal, predominantly axonal but occasionally demyelinating, polyneuropathy.
Patients with TTR-related FAP usually develop insidious onset of numbness and painful paresthesias in the distal lower limbs in the third to fourth decade of life, although some patients develop the disorder later in life (Pattern 2, Table 438-2). Carpal tunnel syndrome (CTS) is common. Autonomic involvement can be severe, leading to postural hypotension, constipation or persistent diarrhea, erectile dysfunction, and impaired sweating (Pattern 10, Table 438-2). Amyloid deposition also occurs in the heart, kidneys, liver, and corneas. Patients usually die 10–15 years after the onset of symptoms from cardiac failure or complications from malnutrition. Because the liver produces much of the body’s TTR, liver transplantation has been used to treat FAP related to TTR mutations. Serum TTR levels decrease after transplantation, and improvement in clinical and EDx features has been reported. Both tafamidis meglumine (20 mg daily) and diflunisal (250 mg twice daily), which prevent misfolding and deposition of mutated TTR, appear to slow the rate of deterioration patients with TTR-related FAP. Recent studies have shown very promising results with gene therapy.
Patients with apolipoprotein A1-related FAP (Van Allen type) usually present in the fourth decade with numbness and painful dysesthesias in the distal limbs. Gradually, the symptoms progress, leading to proximal and distal weakness and atrophy. Although autonomic neuropathy is not severe, some patients develop diarrhea, constipation, or gastroparesis. Most patients die from systemic complications of amyloidosis (e.g., renal failure) 12–15 years after the onset of the neuropathy.
Gelsolin-related amyloidosis (Finnish type) is characterized by the combination of lattice corneal dystrophy and multiple cranial neuropathies that usually begin in the third decade of life. Over time, a mild generalized sensorimotor polyneuropathy develops. Autonomic dysfunction does not occur.
PRIMARY OR AL AMYLOIDOSIS
Besides FAP, amyloidosis can also be acquired (See Chap. 108). In primary or AL amyloidosis, the abnormal protein deposition is composed of immunoglobulin light chains. AL amyloidosis occurs in the setting of multiple myeloma (MM), Waldenström’s macroglobulinemia, lymphoma, other plasmacytomas, or lymphoproliferative disorders, or without any other identifiable disease.
Approximately 30% of patients with AL primary amyloidosis present with a polyneuropathy, most typically painful dysesthesias and burning sensations in the feet (Pattern 2, Table 438-2). However, the trunk can be involved, and some patients manifest with a mononeuropathy multiplex pattern. CTS occurs in 25% of patients and may be the initial manifestation. The neuropathy is slowly progressive, and eventually weakness develops along with large-fiber sensory loss. Most patients develop autonomic involvement with postural hypertension, syncope, bowel and bladder incontinence, constipation, impotence, and impaired sweating (Pattern 10, Table 438-2). Patients generally die from their systemic illness (renal failure, cardiac disease).
The monoclonal protein may be composed of IgG, IgA, IgM, or only free light chain. Lambda (λ) is more common than κ light chain (>2:1) in AL amyloidosis. The CSF protein is often increased (with normal cell count), and thus the neuropathy may be mistaken for CIDP (Chap. 439). Nerve biopsies reveal axonal degeneration and amyloid deposition in either a globular or diffuse pattern infiltrating the perineurial, epineurial, and endoneurial connected tissue and in blood vessel walls.
The median survival of patients with primary amyloidosis is <2 years, with death usually from progressive congestive heart failure or renal failure. Chemotherapy with melphalan, prednisone, and colchicine, to reduce the concentration of monoclonal proteins, and autologous stem cell transplantation may prolong survival, but whether the neuropathy improves is controversial.
DM is the most common cause of peripheral neuropathy in developed countries. DM is associated with several types of polyneuropathy: distal symmetric sensory or sensorimotor polyneuropathy, autonomic neuropathy, diabetic neuropathic cachexia, polyradiculoneuropathies, cranial neuropathies, and other mononeuropathies. Risk factors for the development of neuropathy include long-standing, poorly controlled DM and the presence of retinopathy and nephropathy.
Diabetic Distal Symmetric Sensory and Sensorimotor Polyneuropathy (DSPN)
DSPN is the most common form of diabetic neuropathy and manifests as sensory loss beginning in the toes that gradually progresses over time up the legs and into the fingers and arms (Pattern 2, Table 438-2). When severe, a patient may develop sensory loss in the trunk (chest and abdomen), initially in the midline anteriorly and later extending laterally. Tingling, burning, deep aching pains may also be apparent. NCS usually show reduced amplitudes and mild to moderate slowing of conduction velocities. Nerve biopsy reveals axonal degeneration, endothelial hyperplasia, and, occasionally, perivascular inflammation. Tight control of glucose can reduce the risk of developing neuropathy or improve the underlying neuropathy. A variety of medications have been used with variable success to treat painful symptoms associated with DSPN, including antiepileptic medications, antidepressants, sodium channel blockers, and other analgesics (Table 438-6). For those patients with inadequate pain control despite adequate trials of medications, 10-kHz spinal cord stimulation has been shown in a small trial to be of potential benefit.
TABLE 438-6Treatment of Painful Sensory Neuropathies ||Download (.pdf) TABLE 438-6 Treatment of Painful Sensory Neuropathies
|Therapy ||Route ||Dose ||Side Effects |
|Lidoderm 5% patch ||Apply to painful area ||Up to 3 patches qd ||Skin irritation |
|Tricyclic antidepressants (e.g., amitriptyline, nortriptyline) ||PO ||10–100 mg qhs ||Cognitive changes, sedation, dry eyes and mouth, urinary retention, constipation |
|Gabapentin ||PO ||300–1200 mg tid ||Cognitive changes, sedation, peripheral edema |
|Pregabalin ||PO ||50–100 mg tid ||Cognitive changes, sedation, peripheral edema |
|Duloxetine ||PO ||30–60 mg qd ||Cognitive changes, sedation, dry eyes, diaphoresis, nausea, diarrhea, constipation |
|Carbamazepine ||PO ||200–400 mg q 6–8 h ||Cognitive changes, dizziness, leukopenia, liver dysfunction |
|Phenytoin ||PO ||200–400 mg qhs ||Cognitive changes, dizziness, liver dysfunction |
|Venlafaxine ||PO ||37.5–150 mg/d ||Asthenia, sweating, nausea, constipation, anorexia, vomiting, somnolence, dry mouth, dizziness, nervousness, anxiety, tremor, and blurred vision as well as abnormal ejaculation/orgasm and impotence |
|Tramadol ||PO ||50 mg qid ||Cognitive changes, gastrointestinal upset |
|Mexiletine ||PO ||200–300 mg tid ||Arrhythmias |
|Other Agents |
|EMLA cream ||Apply cutaneously ||qid ||Local erythema |
|2.5% lidocaine || || || |
|2.5% prilocaine || || || |
|Capsaicin 0.025–0.075% cream ||Apply cutaneously ||qid ||Painful burning skin |
Diabetic Autonomic Neuropathy
Autonomic neuropathy is typically seen in combination with DSPN. The autonomic neuropathy can manifest as abnormal sweating, dysfunctional thermoregulation, dry eyes and mouth, pupillary abnormalities, cardiac arrhythmias, postural hypotension, GI abnormalities (e.g., gastroparesis, postprandial bloating, chronic diarrhea, or constipation), and genitourinary dysfunction (e.g., impotence, retrograde ejaculation, incontinence) (Pattern 10, Table 438-2). Tests of autonomic function are generally abnormal, including sympathetic skin responses and quantitative sudomotor axon reflex testing. Sensory and motor NCS generally demonstrate features described above with DSPN.
Diabetic Radiculoplexus Neuropathy (Diabetic Amyotrophy or Bruns-Garland Syndrome)
Diabetic radiculoplexus neuropathy is the presenting manifestation of DM in approximately one-third of patients. Typically, patients present with severe pain in the low back, hip, and thigh in one leg. Rarely, the diabetic polyradiculoneuropathy begins in both legs at the same time (Pattern 4, Table 438-2). Atrophy and weakness of proximal and distal muscles in the affected leg become apparent within a few days or weeks. The neuropathy is often accompanied or heralded by severe weight loss. Weakness usually progresses over several weeks or months, but can continue to progress for 18 months or more. Subsequently, there is slow recovery but many are left with residual weakness, sensory loss, and pain. In contrast to the more typical lumbosacral radiculoplexus neuropathy, some patients develop thoracic radiculopathy or, even less commonly, a cervical polyradiculoneuropathy. CSF protein is usually elevated, while the cell count is normal. ESR is often increased. EDx reveals evidence of active denervation in affected proximal and distal muscles in the affected limbs and in paraspinal muscles. Nerve biopsies may demonstrate axonal degeneration along with perivascular inflammation. Patients with severe pain are sometimes treated in the acute period with glucocorticoids, although a randomized controlled trial has yet to be performed, and the natural history of this neuropathy is gradual improvement.
Diabetic Mononeuropathies or Multiple Mononeuropathies
The most common mononeuropathies are median neuropathy at the wrist and ulnar neuropathy at the elbow, but peroneal neuropathy at the fibular head, and sciatic, lateral femoral, cutaneous, or cranial neuropathies also occur (Pattern 3, Table 438-2). In regard to cranial mononeuropathies, seventh nerve palsies are relatively common but may have other, nondiabetic etiologies. In diabetics, a third nerve palsy is most common, followed by sixth nerve, and, less frequently, fourth nerve palsies. Diabetic third nerve palsies are characteristically pupil-sparing (Chap. 28).
Hypothyroidism is more commonly associated with a proximal myopathy, but some patients develop a neuropathy, most typically CTS. Rarely, a generalized sensory polyneuropathy characterized by painful paresthesias and numbness in both the legs and hands can occur. Treatment is correction of the hypothyroidism.
Sjögren’s syndrome, characterized by the sicca complex of xerophthalmia, xerostomia, and dryness of other mucous membranes, can be complicated by neuropathy (Chap. 354). Most common is a length-dependent axonal sensorimotor neuropathy characterized mainly by sensory loss in the distal extremities (Pattern 2, Table 438-2). A pure small-fiber neuropathy or a cranial neuropathy, particularly involving the trigeminal nerve, can also be seen. Sjögren’s syndrome is also associated with sensory neuronopathy/ganglionopathy. Patients with sensory ganglionopathies develop progressive numbness and tingling of the limbs, trunk, and face in a non-length-dependent manner such that symptoms can involve the face or arms more than the legs. The onset can be acute or insidious. Sensory examination demonstrates severe vibratory and proprioceptive loss leading to sensory ataxia.
Patients with neuropathy due to Sjögren’s syndrome may have ANAs, SS-A/Ro, and SS-B/La antibodies in the serum, but most do not. NCS demonstrate reduced amplitudes of sensory studies in the affected limbs. Nerve biopsy demonstrates axonal degeneration. Nonspecific perivascular inflammation may be present, but only rarely is there necrotizing vasculitis. There is no specific treatment for neuropathies related to Sjögren’s syndrome. When vasculitis is suspected, immunosuppressive agents may be beneficial. Occasionally, the sensory neuronopathy/ganglionopathy stabilizes or improves with immunotherapy, such as IVIg.
Peripheral neuropathy occurs in at least 50% of patients with rheumatoid arthritis (RA) and may be vasculitic in nature (Chap. 351). Vasculitic neuropathy can present with a mononeuropathy multiplex (Pattern 3, Table 438-2), a generalized symmetric pattern of involvement (Pattern 2, Table 438-2), or a combination of these patterns (Chap. 356). Neuropathies may also result from drugs used to treat RA (e.g., tumor necrosis blockers, leflunomide). Nerve biopsy often reveals thickening of the epineurial and endoneurial blood vessels as well as perivascular inflammation or vasculitis, with transmural inflammatory cell infiltration and fibrinoid necrosis of vessel walls. The neuropathy is usually responsive to immunomodulating therapies.
SYSTEMIC LUPUS ERYTHEMATOSUS
Between 2 and 27% of individuals with SLE develop a peripheral neuropathy (Chap. 349). Affected patients typically present with a slowly progressive sensory loss beginning in the feet. Some patients develop burning pain and paresthesias with normal reflexes, and NCS suggest a pure small-fiber neuropathy (Pattern 2, Table 438-2). Less common are multiple mononeuropathies presumably secondary to necrotizing vasculitis (Pattern 3, Table 438-2). Rarely, a generalized sensorimotor polyneuropathy meeting clinical, laboratory, electrophysiologic, and histologic criteria for either GBS or CIDP may occur. Immunosuppressive therapy may be beneficial in SLE patients with neuropathy due to vasculitis. Immunosuppressive agents are less likely to be effective in patients with a generalized sensory or sensorimotor polyneuropathy without evidence of vasculitis. Patients with a GBS or CIDP-like neuropathy should be treated accordingly (Chap. 439).
SYSTEMIC SCLEROSIS (SCLERODERMA)
A distal symmetric, mainly sensory, polyneuropathy complicates 5–67% of scleroderma cases (Pattern 2, Table 438-2) (Chap. 353). Cranial mononeuropathies can also develop, most commonly of the trigeminal nerve, producing numbness and dysesthesias in the face. Multiple mononeuropathies also occur (Pattern 3, Table 438-2). The EDx and histologic features of nerve biopsy are those of an axonal sensory greater than motor polyneuropathy.
MIXED CONNECTIVE TISSUE DISEASE (MCTD)
A mild distal axonal sensorimotor polyneuropathy occurs in ~10% of patients with MCTD.
The peripheral or CNS is involved in about 5% of patients with sarcoidosis (Chap. 360). The most common cranial nerve involved is the seventh nerve, which can be affected bilaterally. Some patients develop radiculopathy or polyradiculopathy (Pattern 4, Table 438-2). With a generalized root involvement, the clinical presentation can mimic GBS or CIDP. Patients can also present with multiple mononeuropathies (Pattern 3, Table 438-2) or a generalized, slowly progressive, sensory greater than motor polyneuropathy (Pattern 2, Table 438-2). Some have features of a pure small-fiber neuropathy. EDx reveals an axonal neuropathy. Nerve biopsy can reveal noncaseating granulomas infiltrating the endoneurium, perineurium, or epineurium along with lymphocytic necrotizing angiitis. Neurosarcoidosis may respond to treatment with glucocorticoids or other immunosuppressive agents.
Hypereosinophilic syndrome is characterized by eosinophilia associated with various skin, cardiac, hematologic, and neurologic abnormalities. A generalized peripheral neuropathy or a mononeuropathy multiplex occurs in 6–14% of patients (Pattern 2, Table 438-2).
CELIAC DISEASE (GLUTEN-INDUCED ENTEROPATHY OR NONTROPICAL SPRUE)
Neurologic complications, particularly ataxia and peripheral neuropathy, are estimated to occur in 10% of patients with celiac disease (Chap. 318). A generalized sensorimotor polyneuropathy, pure motor neuropathy, multiple mononeuropathies, autonomic neuropathy, small-fiber neuropathy, and neuromyotonia have all been reported in association with celiac disease or antigliadin/antiendomysial antibodies (Patterns 2, 3, and 9; Table 438-2). Nerve biopsy may reveal a loss of large myelinated fibers. The neuropathy may be secondary to malabsorption of vitamins B12 and E. However, some patients have no appreciable vitamin deficiencies. The pathogenic basis for the neuropathy in these patients is unclear but may be autoimmune in etiology. The neuropathy does not appear to respond to a gluten-free diet. In patients with vitamin B12 or vitamin E deficiency, replacement therapy may improve or stabilize the neuropathy.
INFLAMMATORY BOWEL DISEASE
Ulcerative colitis and Crohn’s disease may be complicated by GBS, CIDP, generalized axonal sensory or sensorimotor polyneuropathy, small-fiber neuropathy, or mononeuropathy (Patterns 2 and 3, Table 438-2) (Chap. 319). These neuropathies may be autoimmune, nutritional (e.g., vitamin B12 deficiency), treatment related (e.g., metronidazole), or idiopathic in nature. An acute neuropathy with demyelination resembling GBS, CIDP, or multifocal motor neuropathy may occur in patients treated with tumor necrosis factor α blockers.
Approximately 60% of patients with renal failure develop a polyneuropathy characterized by length-dependent numbness, tingling, allodynia, and mild distal weakness (Pattern 2, Table 438-2). Rarely, a rapidly progressive weakness and sensory loss very similar to GBS can occur that improves with an increase in the intensity of renal dialysis or with transplantation (Pattern 1, Table 438-2). Mononeuropathies can also occur, the most common of which is CTS. Ischemic monomelic neuropathy (see below) can complicate arteriovenous shunts created in the arm for dialysis (Pattern 3, Table 438-2). EDx in uremic patients reveals features of a length-dependent, primarily axonal, sensorimotor polyneuropathy. Sural nerve biopsies demonstrate a loss of nerve fibers (particularly large myelinated nerve fibers), active axonal degeneration, and segmental and paranodal demyelination. The sensorimotor polyneuropathy can be stabilized by hemodialysis and improved with successful renal transplantation.
A generalized sensorimotor neuropathy characterized by numbness, tingling, and minor weakness in the distal aspects of primarily the lower limbs commonly occurs in patients with chronic liver failure. EDx studies are consistent with a sensory greater than motor axonopathy. Occasionally patients with severe liver disease develop a combined neuropathy and myopathy. Sural nerve biopsy reveals both segmental demyelination and axonal loss. It is not known if hepatic failure in isolation can cause peripheral neuropathy, as the majority of patients have liver disease secondary to other disorders, such as alcoholism or viral hepatitis, which can also cause neuropathy.
CRITICAL ILLNESS POLYNEUROPATHY
The most common causes of acute generalized weakness leading to admission to a medical intensive care unit (ICU) are GBS and myasthenia gravis (Pattern 1, Table 438-2) (Chaps. 439 and 440). However, weakness developing in critically ill patients while in the ICU is usually caused by critical illness polyneuropathy (CIP) or critical illness myopathy (CIM) or, much less commonly, by prolonged neuromuscular blockade. From a clinical and EDx standpoint, it can be quite difficult to distinguish these disorders. Most specialists believe that CIM is more common. Both CIM and CIP develop as a complication of sepsis and multiple organ failure. They usually present as an inability to wean a patient from a ventilator. A coexisting encephalopathy may limit the neurologic examination, in particular the sensory examination. Muscle stretch reflexes are absent or reduced.
Serum creatine kinase (CK) is usually normal; an elevated serum CK would point to CIM as opposed to CIP. NCS reveal absent or markedly reduced amplitudes of motor and sensory studies in CIP, whereas sensory studies are relatively preserved in CIM. Needle EMG usually reveals profuse positive sharp waves and fibrillation potentials, and it is not unusual in patients with severe weakness to be unable to recruit motor unit action potentials. The pathogenic basis of CIP is not known. Perhaps circulating toxins and metabolic abnormalities associated with sepsis and multiorgan failure impair axonal transport or mitochondrial function, leading to axonal degeneration.
LEPROSY (HANSEN’S DISEASE)
Leprosy, caused by the acid-fast bacteria Mycobacterium leprae, is the most common cause of peripheral neuropathy in Southeast Asia, Africa, and South America (Chap. 174). Clinical manifestations range from tuberculoid leprosy at one end of the spectrum to lepromatous leprosy at the other end, with borderline leprosy in between. Neuropathies are most common in patients with borderline leprosy. Superficial cutaneous nerves of the ears and distal limbs are commonly affected. Mononeuropathies, multiple mononeuropathies, or a slowly progressive symmetric sensorimotor polyneuropathy may develop (Patterns 2 and 3, Table 438-2). Sensory NCS are usually absent in the lower limb and are reduced in amplitude in the arms. Motor NCS may demonstrate reduced amplitudes in affected nerves but occasionally can reveal demyelinating features. Leprosy is usually diagnosed by skin lesion biopsy. Nerve biopsy can also be diagnostic, particularly when there are no apparent skin lesions. The tuberculoid form is characterized by granulomas, and bacilli are not seen. In contrast, with lepromatous leprosy, large numbers of infiltrating bacilli, TH2 lymphocytes, and organism-laden, foamy macrophages with minimal granulomatous infiltration are evident. The bacilli are best appreciated using the Fite stain, where they can be seen as red-staining rods often in clusters free in the endoneurium, within macrophages, or within Schwann cells.
Patients are generally treated with multiple drugs: dapsone, rifampin, and clofazimine. Other medications that are used include thalidomide, pefloxacin, ofloxacin, sparfloxacin, minocycline, and clarithromycin. Patients are generally treated for 2 years. Treatment is sometimes complicated by the so-called reversal reaction, particularly in borderline leprosy. The reversal reaction can occur at any time during treatment and develops because of a shift to the tuberculoid end of the spectrum, with an increase in cellular immunity during treatment. The cellular response is upregulated as evidenced by an increased release of tumor necrosis factor α, interferon γ, and interleukin 2, with new granuloma formation. This can result in an exacerbation of the rash and the neuropathy as well as in appearance of new lesions. High-dose glucocorticoids blunt this adverse reaction and may be used prophylactically at treatment onset in high-risk patients. Erythema nodosum leprosum (ENL) is also treated with glucocorticoids or thalidomide.
Lyme disease is caused by infection with Borrelia burgdorferi, a spirochete usually transmitted by the deer tick Ixodes dammini (Chap. 181). Neurologic complications may develop during the second and third stages of infection. Facial neuropathy is most common and is bilateral in about half of cases, which is rare for idiopathic Bell’s palsy. Involvement of nerves is frequently asymmetric. Some patients present with a polyradiculoneuropathy or multiple mononeuropathies (Pattern 3 or 4, Table 438-2). EDx is suggestive of a primary axonopathy. Nerve biopsies can reveal axonal degeneration with perivascular inflammation. Treatment is with antibiotics (Chap. 181).
Diphtheria is caused by the bacteria Corynebacterium diphtheriae (Chap. 145). Infected individuals present with flulike symptoms of generalized myalgias, headache, fatigue, low-grade fever, and irritability within a week to 10 days of the exposure. About 20–70% of patients develop a peripheral neuropathy caused by a toxin released by the bacteria. Three to four weeks after infection, patients may note decreased sensation in their throat and begin to develop dysphagia, dysarthria, hoarseness, and blurred vision due to impaired accommodation. A generalized polyneuropathy may manifest 2 or 3 months following the initial infection, characterized by numbness, paresthesias, and weakness of the arms and legs and occasionally ventilatory failure (Pattern 1, Table 438-2). CSF protein can be elevated with or without lymphocytic pleocytosis. EDx suggests a diffuse axonal sensorimotor polyneuropathy. Antitoxin and antibiotics should be given within 48 h of symptom onset. Although early treatment reduces the incidence and severity of some complications (i.e., cardiomyopathy), it does not appear to alter the natural history of the associated peripheral neuropathy. The neuropathy usually resolves after several months.
HUMAN IMMUNODEFICIENCY VIRUS
HIV infection can result in a variety of neurologic complications, including peripheral neuropathies (Chap. 197). Approximately 20% of HIV-infected individuals develop a neuropathy either as a direct result of the virus itself, other associated viral infections (e.g., CMV), or neurotoxicity secondary to antiviral medications (see below). The major presentations of peripheral neuropathy associated with HIV infection include (1) distal symmetric polyneuropathy (DSP), (2) inflammatory demyelinating polyneuropathy (including both GBS and CIDP), (3) multiple mononeuropathies (e.g., vasculitis, CMV-related), (4) polyradiculopathy (usually CMV-related), (5) autonomic neuropathy, and (6) sensory ganglionitis.
HIV-Related Distal Symmetric Polyneuropathy
DSP is the most common form of peripheral neuropathy associated with HIV infection and usually is seen in patients with AIDS. It is characterized by numbness and painful paresthesias involving the distal extremities (Pattern 2, Table 438-2). The pathogenic basis for DSP is unknown but is not due to actual infection of the peripheral nerves. The neuropathy may be immune mediated, perhaps caused by the release of cytokines from surrounding inflammatory cells. Vitamin B12 deficiency may contribute in some instances but is not a major cause of most cases of DSP. Older antiretroviral agents (e.g., dideoxycytidine, dideoxyinosine, stavudine) are also neurotoxic and can cause a painful sensory neuropathy.
HIV-Related Inflammatory Demyelinating Polyradiculoneuropathy
Both acute inflammatory demyelinating polyneuropathy (AIDP) and CIDP can occur as a complication of HIV infection (Pattern 1, Table 438-2). AIDP usually develops at the time of seroconversion, whereas CIDP can occur any time in the course of the infection. Clinical and EDx features are indistinguishable from idiopathic AIDP or CIDP (Chap. 439). In addition to elevated protein levels, lymphocytic pleocytosis is evident in the CSF, a finding that helps distinguish this HIV-associated polyradiculoneuropathy from idiopathic AIDP/CIDP.
HIV-Related Progressive Polyradiculopathy
An acute, progressive lumbosacral polyradiculoneuropathy usually secondary to CMV infection can develop in patients with AIDS (Pattern 4, Table 438-2). Patients present with severe radicular pain, numbness, and weakness in the legs, which is usually asymmetric. CSF is abnormal, demonstrating a high protein level, along with a reduced glucose concentration and notably a neutrophilic pleocytosis. EDx studies reveal features of active axonal degeneration. The polyradiculoneuropathy may improve with antiviral therapy.
HIV-Related Multiple Mononeuropathies
Multiple mononeuropathies can also develop in patients with HIV infection, usually in the context of AIDS. Weakness, numbness, paresthesias, and pain occur in the distribution of affected nerves (Pattern 3, Table 438-2). Nerve biopsies can reveal axonal degeneration with necrotizing vasculitis or perivascular inflammation. Glucocorticoid treatment is indicated for vasculitis directly due to HIV infection.
HIV-Related Sensory Neuronopathy/Ganglionopathy
Dorsal root ganglionitis is a very rare complication of HIV infection, and neuronopathy can be the presenting manifestation. Patients develop sensory ataxia similar to idiopathic sensory neuronopathy/ganglionopathy (Pattern 9, Table 438-2). NCS reveal reduced amplitudes or absence of sensory nerve action potentials (SNAPs).
HERPES VARICELLA-ZOSTER VIRUS
Peripheral neuropathy from herpes varicella-zoster (HVZ) infection results from reactivation of latent virus or from a primary infection (Chap. 188). Two-thirds of infections in adults are characterized by dermal zoster in which severe pain and paresthesias develop in a dermatomal region followed within a week or two by a vesicular rash in the same distribution (Pattern 3, Table 438-2). Weakness in muscles innervated by roots corresponding to the dermatomal distribution of skin lesions occurs in 5–30% of patients. Approximately 25% of affected patients have continued pain (postherpetic neuralgia [PHN]). A large clinical trial demonstrated that vaccination against zoster reduces the incidence of HVZ among vaccine recipients by 51% and reduces the incidence of PHN by 67%. Treatment of PHN is symptomatic (Table 438-6).
CMV can cause an acute lumbosacral polyradiculopathy and multiple mononeuropathies in patients with HIV infection and in other immune deficiency conditions (Pattern 4, Table 438-2) (Chap. 190).
EBV infection has been associated with GBS, cranial neuropathies, mononeuropathy multiplex, brachial plexopathy, lumbosacral radiculoplexopathy, and sensory neuronopathies (Patterns 1, 3, 4, and 9, Table 438-2) (Chap. 189).
Hepatitis B and C can cause multiple mononeuropathies related to vasculitis, AIDP, or CIDP (Patterns 1 and 3, Table 438-2) (Chap. 334).
NEUROPATHIES ASSOCIATED WITH MALIGNANCY
Patients with malignancy can develop neuropathies due to (1) a direct effect of the cancer by invasion or compression of the nerves, (2) remote or paraneoplastic effect, (3) a toxic effect of treatment, or (4) as a consequence of immune compromise caused by immunosuppressive medications. The most common associated malignancy is lung cancer, but neuropathies also complicate carcinoma of the breast, ovaries, stomach, colon, rectum, and other organs, including the lymphoproliferative system.
PARANEOPLASTIC SENSORY NEURONOPATHY/GANGLIONOPATHY
Paraneoplastic encephalomyelitis/sensory neuronopathy (PEM/SN) usually complicates small-cell lung carcinoma (Chap. 90). Patients usually present with numbness and paresthesias in the distal extremities that are often asymmetric. The onset can be acute or insidiously progressive. Prominent loss of proprioception leads to sensory ataxia (Pattern 9; Table 438-2). Weakness can be present, usually secondary to an associated myelitis, motor neuronopathy, or concurrent LEMS. Many patients also develop confusion, memory loss, depression, hallucinations or seizures, or cerebellar ataxia. Polyclonal antineuronal antibodies (IgG) directed against a 35- to 40-kDa protein or complex of proteins, the so-called Hu antigen, are found in the sera or CSF in the majority of patients with paraneoplastic PEM/SN. CSF may be normal or may demonstrate mild lymphocytic pleocytosis and elevated protein. PEM/SN is probably the result of antigenic similarity between proteins expressed in the tumor cells and neuronal cells, leading to an immune response directed against both cell types. Treatment of the underlying cancer generally does not affect the course of PEM/SN. However, occasional patients may improve following treatment of the tumor. Unfortunately, plasmapheresis, intravenous immunoglobulin, and immunosuppressive agents have not shown benefit.
NEUROPATHY SECONDARY TO TUMOR INFILTRATION
Malignant cells, in particular leukemia and lymphoma, can infiltrate cranial and peripheral nerves, leading to mononeuropathy, mononeuropathy multiplex, polyradiculopathy, plexopathy, or even a generalized symmetric distal or proximal and distal polyneuropathy (Patterns 1, 2, 3, and 4; Table 438-2). Neuropathy related to tumor infiltration is often painful; it can be the presenting manifestation of the cancer or the heralding symptom of a relapse. The neuropathy may improve with treatment of the underlying leukemia or lymphoma or with glucocorticoids.
NEUROPATHY AS A COMPLICATION OF BONE MARROW TRANSPLANTATION
Neuropathies may develop in patients who undergo bone marrow transplantation (BMT) because of the toxic effects of chemotherapy, radiation, infection, or an autoimmune response directed against the peripheral nerves. Peripheral neuropathy in BMT is often associated with graft-versus-host disease (GVHD). Chronic GVHD shares many features with a variety of autoimmune disorders, and it is possible that an immune-mediated response directed against peripheral nerves is responsible. Patients with chronic GVHD may develop cranial neuropathies, sensorimotor polyneuropathies, multiple mononeuropathies, and severe generalized peripheral neuropathies resembling AIDP or CIDP (Patterns 1, 2, and 3; Table 438-2). The neuropathy may improve by increasing the intensity of immunosuppressive or immunomodulating therapy and resolution of the GVHD.
Lymphomas may cause neuropathy by infiltration or direct compression of nerves or by a paraneoplastic process. The neuropathy can be purely sensory or motor, but most commonly is sensorimotor. The pattern of involvement may be symmetric, asymmetric, or multifocal, and the course may be acute, gradually progressive, or relapsing and remitting (Patterns 1, 2, and 3; Table 438-2). EDx can be compatible with either an axonal or demyelinating process. CSF may reveal lymphocytic pleocytosis and an elevated protein. Nerve biopsy may demonstrate endoneurial inflammatory cells in both the infiltrative and the paraneoplastic etiologies. A monoclonal population of cells favors lymphomatous invasion. The neuropathy may respond to treatment of the underlying lymphoma or immunomodulating therapies.
MM usually presents in the fifth to seventh decade of life with fatigue, bone pain, anemia, and hypercalcemia (Chap. 107). Clinical and EDx features of neuropathy occur in as many as 40% of patients. The most common pattern is that of a distal, axonal, sensory, or sensorimotor polyneuropathy (Pattern 2; Table 438-2). Less frequently, a chronic demyelinating polyradiculoneuropathy may develop (Pattern 1; Table 438-2) (see POEMS, Chap. 439). MM can be complicated by amyloid polyneuropathy and should be considered in patients with painful paresthesias, loss of pinprick and temperature discrimination, and autonomic dysfunction (suggestive of a small-fiber neuropathy) and CTS. Expanding plasmacytomas can compress cranial nerves and spinal roots as well. A monoclonal protein, usually composed of γ or μ heavy chains or κ light chains, may be identified in the serum or urine. EDx usually shows reduced amplitudes with normal or only mildly abnormal distal latencies and conduction velocities. A superimposed median neuropathy at the wrist is common. Abdominal fat pad, rectal, or sural nerve biopsy can be performed to look for amyloid deposition. Unfortunately, the treatment of the underlying MM does not usually affect the course of the neuropathy.
NEUROPATHIES ASSOCIATED WITH MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE
Toxic Neuropathies Secondary to Chemotherapy
Many of the commonly used chemotherapy agents can cause a toxic neuropathy (Table 438-7). The mechanisms by which these agents cause toxic neuropathies vary, as does the specific type of neuropathy produced. The risk of developing a toxic neuropathy or more severe neuropathy appears to be greater in patients with a preexisting neuropathy (e.g., CMT disease, diabetic neuropathy) and those who also take other potentially neurotoxic drugs (e.g., nitrofurantoin, isoniazid, disulfiram, pyridoxine). Chemotherapeutic agents usually cause a sensory greater than motor length-dependent axonal neuropathy or neuronopathy/ganglionopathy (Patterns 2 and 9; Table 438-2).
TABLE 438-7Toxic Neuropathies Secondary to Chemotherapy ||Download (.pdf) TABLE 438-7 Toxic Neuropathies Secondary to Chemotherapy
|Drug ||Mechanism of Neurotoxicity ||Clinical Features ||Nerve Histopathology ||EMG/NCS |
|Vinca alkaloids (vincristine, vinblastine, vindesine, vinorelbine) ||Interfere with axonal microtubule assembly; impairs axonal transport ||Symmetric, S-M, large-/small-fiber PN; autonomic symptoms common; infrequent cranial neuropathies ||Axonal degeneration of myelinated and unmyelinated fibers; regenerating clusters, minimal segmental demyelination ||Axonal sensorimotor PN; distal denervation on EMG; abnormal QST, particularly vibratory perception |
|Cisplatin || |
Preferential damage to dorsal root ganglia:
? binds to and cross-links DNA
? inhibits protein synthesis
? impairs axonal transport
|Predominant large-fiber sensory neuronopathy; sensory ataxia ||Loss of large > small myelinated and unmyelinated fibers; axonal degeneration with small clusters of regenerating fibers; secondary segmental demyelination ||Low-amplitude or unobtainable SNAPs with normal CMAPs and EMG; abnormal QST, particularly vibratory perception |
|Taxanes (paclitaxel, docetaxel) ||Promotes axonal microtubule assembly; interferes with axonal transport ||Symmetric, predominantly sensory PN; large-fiber modalities affected more than small-fiber ||Loss of large > small myelinated and unmyelinated fibers; axonal degeneration with small clusters of regenerating fibers; secondary segmental demyelination ||Axonal sensorimotor PN; distal denervation on EMG; abnormal QST, particularly vibratory perception |
|Suramin || || || || |
| Axonal PN ||Unknown; ? inhibition of neurotrophic growth factor binding; ? neuronal lysosomal storage ||Symmetric, length-dependent, sensory-predominant PN ||None described ||Abnormalities consistent with an axonal S-M PN |
| Demyelinating PN ||Unknown; ? immunomodulating effects ||Subacute, S-M PN with diffuse proximal and distal weakness; areflexia; increased CSF protein ||Loss of large and small myelinated fibers with primary demyelination and secondary axonal degeneration; occasional epi- and endoneurial inflammatory cell infiltrates ||Features suggestive of an acquired demyelinating sensorimotor PN (e.g., slow CVs, prolonged distal latencies and F-wave latencies, conduction block, temporal dispersion) |
|Cytarabine (ARA-C) ||Unknown; ? selective Schwann cell toxicity; ? immunomodulating effects ||GBS-like syndrome; pure sensory neuropathy; brachial plexopathy ||Loss of myelinated nerve fibers; axonal degeneration; segmental demyelination; no inflammation ||Axonal, demyelinating, or mixed S-M PN; denervation on EMG |
|Etoposide (VP-16) ||Unknown; ? selective dorsal root ganglia toxicity ||Length-dependent, sensory-predominant PN; autonomic neuropathy ||None described ||Abnormalities consistent with an axonal S-M PN |
|Bortezomib (Velcade) ||Unknown ||Length-dependent, sensory, predominantly small-fiber PN ||Not reported ||Abnormalities consistent with an axonal sensory neuropathy with early small-fiber involvement (abnormal autonomic studies) |
Neuropathies can develop as complications of toxic effects of various drugs and other environmental exposures (Table 438-8). The more common neuropathies associated with these agents are discussed here.
TABLE 438-8Toxic Neuropathies ||Download (.pdf) TABLE 438-8 Toxic Neuropathies
|Drug ||Mechanism of Neurotoxicity ||Clinical Features ||Nerve Histopathology ||EMG/NCS |
|Misonidazole ||Unknown ||Painful paresthesias and loss of large- and small-fiber sensory modalities and sometimes distal weakness in length-dependent pattern ||Axonal degeneration of large myelinated fibers; axonal swellings; segmental demyelination ||Low-amplitude or unobtainable SNAPs with normal or only slightly reduced CMAPs amplitudes |
|Metronidazole ||Unknown ||Painful paresthesias and loss of large- and small-fiber sensory modalities and sometimes distal weakness in length-dependent pattern ||Axonal degeneration ||Low-amplitude or unobtainable SNAPs with normal CMAPs |
|Chloroquine and hydroxychloroquine ||Amphiphilic properties may lead to drug-lipid complexes that are indigestible and result in accumulation of autophagic vacuoles ||Loss of large- and small-fiber sensory modalities and distal weakness in length-dependent pattern; superimposed myopathy may lead to proximal weakness ||Axonal degeneration with autophagic vacuoles in nerves as well as muscle fibers ||Low-amplitude or unobtainable SNAPs with normal or reduced CMAP amplitudes; distal denervation on EMG; irritability and myopathic-appearing MUAPs proximally in patients with superimposed toxic myopathy |
|Amiodarone ||Amphiphilic properties may lead to drug-lipid complexes that are indigestible and result in accumulation of autophagic vacuoles ||Paresthesias and pain with loss of large- and small-fiber sensory modalities and distal weakness in length-dependent pattern; superimposed myopathy may lead to proximal weakness ||Axonal degeneration and segmental demyelination with myeloid inclusions in nerves and muscle fibers ||Low-amplitude or unobtainable SNAPs with normal or reduced CMAP amplitudes; can also have prominent slowing of CVs; distal denervation on EMG; irritability and myopathic-appearing MUAPs proximally in patients with superimposed toxic myopathy |
|Colchicine ||Inhibits polymerization of tubulin in microtubules and impairs axoplasmic flow ||Numbness and paresthesias with loss of large-fiber modalities in a length-dependent fashion; superimposed myopathy may lead to proximal in addition to distal weakness ||Nerve biopsy demonstrates axonal degeneration; muscle biopsy reveals fibers with vacuoles ||Low-amplitude or unobtainable SNAPs with normal or reduced CMAP amplitudes; irritability and myopathic-appearing MUAPs proximally in patients with superimposed toxic myopathy |
|Podophyllin ||Binds to microtubules and impairs axoplasmic flow ||Sensory loss, tingling, muscle weakness, and diminished muscle stretch reflexes in length-dependent pattern; autonomic neuropathy ||Axonal degeneration ||Low-amplitude or unobtainable SNAPs with normal or reduced CMAP amplitudes |
|Thalidomide ||Unknown ||Numbness, tingling, and burning pain and weakness in a length-dependent pattern ||Axonal degeneration; autopsy studies reveal degeneration of dorsal root ganglia ||Low-amplitude or unobtainable SNAPs with normal or reduced CMAP amplitudes |
|Disulfiram ||Accumulation of neurofilaments and impaired axoplasmic flow ||Numbness, tingling, and burning pain in a length-dependent pattern ||Axonal degeneration with accumulation of neurofilaments in the axons ||Low-amplitude or unobtainable SNAPs with normal or reduced CMAP amplitudes |
|Dapsone ||Unknown ||Distal weakness that may progress to proximal muscles; sensory loss ||Axonal degeneration and segmental demyelination ||Low-amplitude or unobtainable CMAPs with normal or reduced SNAP amplitudes |
|Leflunomide ||Unknown ||Paresthesias and numbness in a length-dependent pattern ||Unknown ||Low-amplitude or unobtainable SNAPs with normal or reduced CMAP amplitudes |
|Nitrofurantoin ||Unknown ||Numbness, painful paresthesias, and severe weakness that may resemble GBS ||Axonal degeneration; autopsy studies reveal degeneration of dorsal root ganglia and anterior horn cells ||Low-amplitude or unobtainable SNAPs with normal or reduced CMAP amplitudes |
|Pyridoxine (vitamin B6) ||Unknown ||Dysesthesias and sensory ataxia; impaired large-fiber sensory modalities on examination ||Marked loss of sensory axons and cell bodies in dorsal root ganglia ||Reduced amplitudes or absent SNAPs |
|Isoniazid ||Inhibits pyridoxal phosphokinase leading to pyridoxine deficiency ||Dysesthesias and sensory ataxia; impaired large-fiber sensory modalities on examination ||Marked loss of sensory axons and cell bodies in dorsal root ganglia and degeneration of the dorsal columns ||Reduced amplitudes or absent SNAPs and, to a lesser extent, CMAPs |
|Ethambutol ||Unknown ||Numbness with loss of large-fiber modalities on examination ||Axonal degeneration ||Reduced amplitudes or absent SNAPs |
|Antinucleosides ||Unknown ||Dysesthesia and sensory ataxia; impaired large-fiber sensory modalities on examination ||Axonal degeneration ||Reduced amplitudes or absent SNAPs |
|Phenytoin ||Unknown ||Numbness with loss of large-fiber modalities on examination ||Axonal degeneration and segmental demyelination ||Low-amplitude or unobtainable SNAPs with normal or reduced CMAP amplitudes |
|Lithium ||Unknown ||Numbness with loss of large-fiber modalities on examination ||Axonal degeneration ||Low-amplitude or unobtainable SNAPs with normal or reduced CMAP amplitudes |
|Acrylamide ||Unknown; may be caused by impaired axonal transport ||Numbness with loss of large-fiber modalities on examination; sensory ataxia; mild distal weakness ||Degeneration of sensory axons in peripheral nerves and posterior columns, spinocerebellar tracts, mammillary bodies, optic tracts, and corticospinal tracts in the CNS ||Low-amplitude or unobtainable SNAPs with normal or reduced CMAP amplitudes |
|Carbon disulfide ||Unknown ||Length-dependent numbness and tingling with mild distal weakness ||Axonal swellings with accumulation of neurofilaments ||Low-amplitude or unobtainable SNAPs with normal or reduced CMAP amplitudes |
|Ethylene oxide ||Unknown; may act as alkylating agent and bind DNA ||Length-dependent numbness and tingling; may have mild distal weakness ||Axonal degeneration ||Low-amplitude or unobtainable SNAPs with normal or reduced CMAP amplitudes |
|Organophosphates ||Bind and inhibit neuropathy target esterase ||Early features are those of neuromuscular blockade with generalized weakness; later axonal sensorimotor PN ensues ||Axonal degeneration along with degeneration of gracile fasciculus and corticospinal tracts ||Early: repetitive firing of CMAPs and decrement with repetitive nerve stimulation; late: axonal sensorimotor PN |
|Hexacarbons ||Unknown; may lead to covalent cross-linking between neurofilaments ||Acute, severe sensorimotor PN that may resemble GBS ||Axonal degeneration and giant axons swollen with neurofilaments ||Features of a mixed axonal and/or demyelinating sensorimotor axonal PN—reduced amplitudes, prolonged distal latencies, conduction block, and slowing of CVs |
|Lead ||Unknown; may interfere with mitochondria ||Encephalopathy; motor neuropathy (often resembles radial neuropathy with wrist and finger drop); autonomic neuropathy; bluish-black discoloration of gums ||Axonal degeneration of motor axons ||Reduction of CMAP amplitudes with active denervation on EMG |
|Mercury ||Unknown; may combine with sulfhydryl groups ||Abdominal pain and nephrotic syndrome; encephalopathy; ataxia; paresthesias ||Axonal degeneration; degeneration of dorsal root ganglia, calcarine, and cerebellar cortex ||Low-amplitude or unobtainable SNAPs with normal or reduced CMAP amplitudes |
|Thallium ||Unknown ||Encephalopathy; painful sensory symptoms; mild loss of vibration; distal or generalized weakness may also develop; autonomic neuropathy; alopecia ||Axonal degeneration ||Low-amplitude or unobtainable SNAPs with normal or reduced CMAP amplitudes |
|Arsenic ||Unknown; may combine with sulfhydryl groups ||Abdominal discomfort, burning pain, and paresthesias; generalized weakness; autonomic insufficiency; can resemble GBS ||Axonal degeneration ||Low-amplitude or unobtainable SNAPs with normal or reduced CMAP amplitudes; may have demyelinating features: prolonged distal latencies and slowing of CVs |
|Gold ||Unknown ||Distal paresthesias and reduction of all sensory modalities ||Axonal degeneration ||Low-amplitude or unobtainable SNAPs |
Chloroquine and hydroxychloroquine can cause a toxic myopathy characterized by slowly progressive, painless, proximal weakness and atrophy, which is worse in the legs than the arms. In addition, neuropathy can also develop with or without the myopathy leading to sensory loss and distal weakness. The “neuromyopathy” usually appears in patients taking 500 mg daily for a year or more but has been reported with doses as low as 200 mg/d. Serum CK levels are usually elevated due to the superimposed myopathy. NCS reveal mild slowing of motor and sensory NCVs with a mild to moderate reduction in the amplitudes, although NCS may be normal in patients with only the myopathy. EMG demonstrates myopathic muscle action potentials (MUAPs), increased insertional activity in the form of positive sharp waves, fibrillation potentials, and occasionally myotonic potentials, particularly in the proximal muscles. Neurogenic MUAPs and reduced recruitment are found in more distal muscles. Nerve biopsy demonstrates autophagic vacuoles within Schwann cells. Vacuoles may also be evident in muscle biopsies. The pathogenic basis of the neuropathy is not known but may be related to the amphiphilic properties of the drug. These agents contain both hydrophobic and hydrophilic regions that allow them to interact with the anionic phospholipids of cell membranes and organelles. The drug-lipid complexes may be resistant to digestion by lysosomal enzymes, leading to the formation of autophagic vacuoles filled with myeloid debris that may in turn cause degeneration of nerves and muscle fibers. The signs and symptoms of the neuropathy and myopathy are usually reversible following discontinuation of medication.
Amiodarone can cause a neuromyopathy similar to chloroquine and hydroxychloroquine. The neuromyopathy typically appears after patients have taken the medication for 2–3 years. Nerve biopsy demonstrates a combination of segmental demyelination and axonal loss. Electron microscopy reveals lamellar or dense inclusions in Schwann cells, pericytes, and endothelial cells. The inclusions in muscle and nerve biopsies have persisted as long as 2 years following discontinuation of the medication.
Colchicine can also cause a neuromyopathy. Patients usually present with proximal weakness and numbness and tingling in the distal extremities. EDx reveals features of an axonal polyneuropathy. Muscle biopsy reveals a vacuolar myopathy, whereas sensory nerves demonstrate axonal degeneration. Colchicine inhibits the polymerization of tubulin into microtubules. The disruption of the microtubules probably leads to defective intracellular movement of important proteins, nutrients, and waste products in muscle and nerves.
Thalidomide is an immunomodulating agent used to treat MM, GVHD, leprosy, and other autoimmune disorders. Thalidomide is associated with severe teratogenic effects as well as peripheral neuropathy that can be dose-limiting. Patients develop numbness, painful tingling, and burning discomfort in the feet and hands and less commonly muscle weakness and atrophy. Even after stopping the drug for 4–6 years, as many as 50% patients continue to have significant symptoms. NCS demonstrate reduced amplitudes or complete absence of SNAPs, with preserved conduction velocities when obtainable. Motor NCS are usually normal. Nerve biopsy reveals a loss of large-diameter myelinated fibers and axonal degeneration. Degeneration of dorsal root ganglion cells has been reported at autopsy.
PYRIDOXINE (VITAMIN B6) TOXICITY
Pyridoxine is an essential vitamin that serves as a coenzyme for transamination and decarboxylation. However, at high doses (116 mg/d), patients can develop a severe sensory neuropathy with dysesthesias and sensory ataxia. NCS reveal absent or markedly reduced SNAP amplitudes with relatively preserved CMAPs. Nerve biopsy reveals axonal loss of fiber at all diameters. Loss of dorsal root ganglion cells with subsequent degeneration of both the peripheral and central sensory tracts have been reported in animal models.
One of the most common side effects of isoniazid (INH) is peripheral neuropathy. Standard doses of INH (3–5 mg/kg per day) are associated with a 2% incidence of neuropathy, whereas neuropathy develops in at least 17% of patients taking in excess of 6 mg/kg per d. The elderly, malnourished, and “slow acetylators” are at increased risk for developing the neuropathy. INH inhibits pyridoxal phosphokinase, resulting in pyridoxine deficiency and the neuropathy. Prophylactic administration of pyridoxine 100 mg/d can prevent the neuropathy from developing.
The nucleoside analogues zalcitabine (dideoxycytidine or ddC), didanosine (dideoxyinosine or ddI), stavudine (d4T), lamivudine (3TC), and antiretroviral nucleoside reverse transcriptase inhibitor (NRTI) are used to treat HIV infection. One of the major dose-limiting side effects of these medications is a predominantly sensory, length-dependent, symmetrically painful neuropathy (Pattern 2; Table 438-2). Zalcitabine (ddC) is the most extensively studied of the nucleoside analogues, and at doses >0.18 mg/kg per d, it is associated with a subacute onset of severe burning and lancinating pains in the feet and hands. NCS reveal decreased amplitudes of the SNAPs with normal motor studies. The nucleoside analogues inhibit mitochondrial DNA polymerase, which is the suspected pathogenic basis for the neuropathy. Because of a “coasting effect,” patients can continue to worsen even 2–3 weeks after stopping the medication. Following dose reduction, improvement in the neuropathy is seen in most patients after several months (mean time about 10 weeks).
HEXACARBONS (n-HEXANE, METHYL n-BUTYL KETONE)/GLUE SNIFFER’S NEUROPATHY
n-Hexane and methyl n-butyl ketone are water-insoluble industrial organic solvents that are also present in some glues. Exposure through inhalation, accidentally or intentionally (glue sniffing), or through skin absorption can lead to a profound subacute sensory and motor polyneuropathy (Pattern 2; Table 438-2). NCS demonstrate decreased amplitudes of the SNAPs and CMAPs with slightly slow CVs. Nerve biopsy reveals a loss of myelinated fibers and giant axons that are filled with 10-nm neurofilaments. Hexacarbon exposure leads to covalent cross-linking between axonal neurofilaments that result in their aggregation, impaired axonal transport, swelling of the axons, and eventual axonal degeneration.
Lead neuropathy is uncommon, but it can be seen in children who accidentally ingest lead-based paints in older buildings and in industrial workers exposed to lead-containing products. The most common presentation of lead poisoning is an encephalopathy; however, symptoms and signs of a primarily motor neuropathy can also occur. The neuropathy is characterized by an insidious and progressive onset of weakness usually beginning in the arms, in particular involving the wrist and finger extensors, resembling a radial neuropathy. Sensation is generally preserved; however, the autonomic nervous system can be affected (Patterns 2, 3, and 10; Table 438-2). Laboratory investigation can reveal a microcytic hypochromic anemia with basophilic stippling of erythrocytes, an elevated serum lead level, and an elevated serum coproporphyrin level. A 24-h urine collection demonstrates elevated levels of lead excretion. The NCS may reveal reduced CMAP amplitudes, while the SNAPs are typically normal. The pathogenic basis may be related to abnormal porphyrin metabolism. The most important principle of management is to remove the source of the exposure. Chelation therapy with calcium disodium ethylene-diaminetetraacetic acid (EDTA), British anti-Lewisite (BAL), and penicillamine also demonstrates variable efficacy.
Mercury toxicity may occur as a result of exposure to either organic or inorganic mercurials. Mercury poisoning presents with paresthesias in hands and feet that progress proximally and may involve the face and tongue. Motor weakness can also develop. CNS symptoms often overshadow the neuropathy. EDx shows features of a primarily axonal sensorimotor polyneuropathy. The primary site of neuromuscular pathology appears to be the dorsal root ganglia. The mainstay of treatment is removing the source of exposure.
Thallium can exist in a monovalent or trivalent form and is primarily used as a rodenticide. The toxic neuropathy usually manifests as burning paresthesias of the feet, abdominal pain, and vomiting. Increased thirst, sleep disturbances, and psychotic behavior may be noted. Within the first week, patients develop pigmentation of the hair, an acne-like rash in the malar area of the face, and hyperreflexia. By the second and third weeks, autonomic instability with labile heart rate and blood pressure may be seen. Hyporeflexia and alopecia also occur but may not be evident until the third or fourth week following exposure. With severe intoxication, proximal weakness and involvement of the cranial nerves can occur. Some patients require mechanical ventilation due to respiratory muscle involvement. The lethal dose of thallium is variable, ranging from 8 to 15 mg/kg body weight. Death can result in <48 h following a particularly large dose. NCS demonstrate features of a primarily axonal sensorimotor polyneuropathy. With acute intoxication, potassium ferric ferrocyanide II may be effective in preventing absorption of thallium from the gut. However, there may be no benefit once thallium has been absorbed. Unfortunately, chelating agents are not very efficacious. Adequate diuresis is essential to help eliminate thallium from the body without increasing tissue availability from the serum.
Arsenic is another heavy metal that can cause a toxic sensorimotor polyneuropathy. The neuropathy manifests 5–10 days after ingestion of arsenic and progresses for several weeks, sometimes mimicking GBS. The presenting symptoms are typically an abrupt onset of abdominal discomfort, nausea, vomiting, pain, and diarrhea followed within several days by burning pain in the feet and hands. Examination of the skin can be helpful in the diagnosis as the loss of the superficial epidermal layer results in patchy regions of increased or decreased pigmentation on the skin several weeks after an acute exposure or with chronic low levels of ingestion. Mee’s lines, which are transverse lines at the base of the fingernails and toenails, do not become evident until 1 or 2 months after the exposure. Multiple Mee’s lines may be seen in patients with long fingernails who have had chronic exposure to arsenic. Mee’s lines are not specific for arsenic toxicity as they can also be seen following thallium poisoning. Because arsenic is cleared from blood rapidly, the serum concentration of arsenic is not diagnostically helpful. However, arsenic levels are increased in the urine, hair, and fingernails of patients exposed to arsenic. Anemia with stippling of erythrocytes is common, and occasionally pancytopenia and aplastic anemia can develop. Increased CSF protein levels without pleocytosis can be seen; this can lead to misdiagnosis as GBS. NCS are usually suggestive of an axonal sensorimotor polyneuropathy; however, demyelinating features can be present. Chelation therapy with BAL has yielded inconsistent results; therefore, it is not generally recommended.
Pernicious anemia is the most common cause of cobalamin deficiency. Other causes include dietary avoidance (vegetarians), gastrectomy, gastric bypass surgery, inflammatory bowel disease, pancreatic insufficiency, bacterial overgrowth, and possibly histamine-2 blockers and proton pump inhibitors. An underappreciated cause of cobalamin deficiency is food-cobalamin malabsorption. This typically occurs in older individuals and results from an inability to adequately absorb cobalamin in food protein. No apparent cause of deficiency is identified in a significant number of patients with cobalamin deficiency. The use of nitrous oxide as an anesthetic agent or as a recreational drug can produce acute cobalamin deficiency neuropathy and subacute combined degeneration.
Complaints of numb hands typically appear before lower extremity paresthesias are noted. A preferential large-fiber sensory loss affecting proprioception and vibration with sparing of small-fiber modalities is present; an unsteady gait reflects sensory ataxia. These features, coupled with diffuse hyperreflexia and absent Achilles reflexes, should always focus attention on the possibility of cobalamin deficiency (Patterns 2 and 6; Table 438-2). Optic atrophy and, in severe cases, behavioral changes ranging from mild irritability and forgetfulness to severe dementia and frank psychosis may appear. The full clinical picture of subacute combined degeneration is uncommon. CNS manifestations, especially pyramidal tract signs, may be missing, and in fact some patients may only exhibit symptoms of peripheral neuropathy.
EDx shows an axonal sensorimotor neuropathy. CNS involvement produces abnormal somatosensory and visual evoked potential latencies. The diagnosis is confirmed by finding reduced serum cobalamin levels. In up to 40% of patients, anemia and macrocytosis are lacking. Serum methylmalonic acid and homocysteine, the metabolites that accumulate when cobalamin-dependent reactions are blocked, are elevated. Antibodies to intrinsic factor are present in ~60%, and antiparietal cell antibodies in about 90%, of individuals with pernicious anemia.
Cobalamin deficiency can be treated with various regimens of cobalamin. One typical regimen consists of 1000 μg cyanocobalamin IM weekly for 1 month and monthly thereafter. Patients with food cobalamin malabsorption can absorb free cobalamin and therefore can be treated with oral cobalamin supplementation. An oral cobalamin dose of 1000 μg per day should be sufficient. Treatment for cobalamin deficiency usually does not completely reverse the clinical manifestations, and at least 50% of patients exhibit some permanent neurologic deficit.
Thiamine (vitamin B1) deficiency is an uncommon cause of peripheral neuropathy in developed countries. It is now most often seen as a consequence of chronic alcohol abuse, recurrent vomiting, total parenteral nutrition, and bariatric surgery. Thiamine deficiency polyneuropathy can occur in normal, healthy young adults who do not abuse alcohol but who engage in inappropriately restrictive diets. Thiamine is water-soluble. It is present in most animal and plant tissues, but the greatest sources are unrefined cereal grains, wheat germ, yeast, soybean flour, and pork. Beriberi means “I can’t, I can’t” in Singhalese, the language of natives of what was once part of the Dutch East Indies (now Sri Lanka). Dry beriberi refers to neuropathic symptoms. The term wet beriberi is used when cardiac manifestations predominate (in reference to edema). Beriberi was relatively uncommon until the late 1800s when it became widespread among people for whom rice was a dietary mainstay. This epidemic was due to a new technique of processing rice that removed the germ from the rice shaft, rendering the so-called polished rice deficient in thiamine and other essential nutrients.
Symptoms of neuropathy follow prolonged deficiency. These begin with mild sensory loss and/or burning dysesthesias in the toes and feet and aching and cramping in the lower legs. Pain may be the predominant symptom. With progression, patients develop features of a nonspecific generalized polyneuropathy, with distal sensory loss in the feet and hands.
Blood and urine assays for thiamine are not reliable for diagnosis of deficiency. Erythrocyte transketolase activity and the percentage increase in activity (in vitro) following the addition of thiamine pyrophosphate (TPP) may be more accurate and reliable. EDx shows nonspecific findings of an axonal sensorimotor polyneuropathy. When a diagnosis of thiamine deficiency is made or suspected, thiamine replacement should be provided until proper nutrition is restored. Thiamine is usually given intravenously or intramuscularly at a dose of 100 mg/d. Although cardiac manifestations show a striking response to thiamine replacement, neurologic improvement is usually more variable and less dramatic.
The term vitamin E is usually used for a-tocopherol, the most active of the four main types of vitamin E. Because vitamin E is present in animal fat, vegetable oils, and various grains, deficiency is usually due to factors other than insufficient intake. Vitamin E deficiency usually occurs secondary to lipid malabsorption or in uncommon disorders of vitamin E transport. One hereditary disorder is abetalipoproteinemia, a rare autosomal dominant disorder characterized by steatorrhea, pigmentary retinopathy, acanthocytosis, and progressive ataxia. Patients with cystic fibrosis may also have vitamin E deficiency secondary to steatorrhea. There are genetic forms of isolated vitamin E deficiency not associated with lipid malabsorption. Vitamin E deficiency may also occur as a consequence of various cholestatic and hepatobiliary disorders as well as short-bowel syndromes resulting from the surgical treatment of intestinal disorders.
Clinical features may not appear until many years after the onset of deficiency. The onset of symptoms tends to be insidious, and progression is slow. The main clinical features are spinocerebellar ataxia and polyneuropathy, thus resembling Friedreich’s ataxia or other spinocerebellar ataxias. Patients manifest progressive ataxia and signs of posterior column dysfunction, such as impaired joint position and vibratory sensation. Because of the polyneuropathy, there is hyporeflexia, but plantar responses may be extensor as a result of the spinal cord involvement (Patterns 2 and 6; Table 438-2). Other neurologic manifestations may include ophthalmoplegia, pigmented retinopathy, night blindness, dysarthria, pseudoathetosis, dystonia, and tremor. Vitamin E deficiency may present as an isolated polyneuropathy, but this is very rare. The yield of checking serum vitamin E levels in patients with isolated polyneuropathy is extremely low, and this test should not be part of routine practice.
Diagnosis is made by measuring a-tocopherol levels in the serum. EDx shows features of an axonal neuropathy. Treatment is replacement with oral vitamin E, but high doses are not needed. For patients with isolated vitamin E deficiency, treatment consists of 1500–6000 IU/d in divided doses.
Vitamin B6, or pyridoxine, can produce neuropathic manifestations from both deficiency and toxicity. Vitamin B6 toxicity was discussed above. Vitamin B6 deficiency is most commonly seen in patients treated with isoniazid or hydralazine. The polyneuropathy of vitamin B6 is nonspecific, manifesting as a generalized axonal sensorimotor polyneuropathy. Vitamin B6 deficiency can be detected by direct assay. Vitamin B6 supplementation with 50–100 mg/d is suggested for patients being treated with isoniazid or hydralazine. This same dose is appropriate for replacement in cases of nutritional deficiency.
PELLAGRA (NIACIN DEFICIENCY)
Pellagra is produced by deficiency of niacin. Although pellagra may be seen in alcoholics, this disorder has essentially been eradicated in most Western countries by means of enriching bread with niacin. Nevertheless, pellagra continues to be a problem in a number of underdeveloped regions, particularly in Asia and Africa, where corn is the main source of carbohydrate. Neurologic manifestations are variable; abnormalities can develop in the brain and spinal cord as well as peripheral nerves. When peripheral nerves are involved, the neuropathy is usually mild and resembles beriberi. Treatment is with niacin 40–250 mg/d.
A syndrome that has only recently been described is myeloneuropathy secondary to copper deficiency. Most patients present with lower limb paresthesias, weakness, spasticity, and gait difficulties (Pattern 6; Table 438-2). Large-fiber sensory function is impaired, reflexes are brisk, and plantar responses are extensor. In some cases, light touch and pinprick sensation are affected, and NCS indicate sensorimotor axonal polyneuropathy in addition to myelopathy.
Hematologic abnormalities are a known complication of copper deficiency; these can include microcytic anemia, neutropenia, and occasionally pancytopenia. Because copper is absorbed in the stomach and proximal jejunum, many cases of copper deficiency occur in the setting of prior gastric surgery. Excess zinc is an established cause of copper deficiency. Zinc upregulates enterocyte production of metallothionine, which results in decreased absorption of copper. Excessive dietary zinc supplements or denture cream containing zinc can produce this clinical picture. Other potential causes of copper deficiency include malnutrition, prematurity, total parenteral nutrition, and ingestion of copper-chelating agents.
Following oral or IV copper replacement, some patients show neurologic improvement, but this may take many months or not occur at all. Replacement consists of oral copper sulfate or gluconate 2 mg one to three times a day. If oral copper replacement is not effective, elemental copper in the copper sulfate or copper chloride forms can be given as 2 mg IV daily for 3–5 days, then weekly for 1–2 months until copper levels normalize. Thereafter, oral daily copper therapy can be resumed. In contrast to the neurologic manifestations, most of the hematologic indices normalize in response to copper replacement therapy.
NEUROPATHY ASSOCIATED WITH GASTRIC SURGERY
Polyneuropathy may occur following gastric surgery for ulcer, cancer, or weight reduction. This usually occurs in the context of rapid, significant weight loss and recurrent, protracted vomiting. The clinical picture is one of acute or subacute sensory loss and weakness. Neuropathy following weight loss surgery usually occurs in the first several months after surgery. Weight reduction surgical procedures include gastrojejunostomy, gastric stapling, vertical banded gastroplasty, and gastrectomy with Roux-en-Y anastomosis. The initial manifestations are usually numbness and paresthesias in the feet (Pattern 2; Table 438-2). In many cases, no specific nutritional deficiency factor is identified.
Management consists of parenteral vitamin supplementation, especially including thiamine. Improvement has been observed following supplementation, parenteral nutritional support, and reversal of the surgical bypass. The duration and severity of deficits before identification and treatment of neuropathy are important predictors of final outcome.
CRYPTOGENIC (IDIOPATHIC) SENSORY AND SENSORIMOTOR POLYNEUROPATHY
Cryptogenic (idiopathic) sensory and sensorimotor polyneuropathy (CSPN) is a diagnosis of exclusion, established after a careful medical, family, and social history; neurologic examination; and directed laboratory testing. Despite extensive evaluation, the cause of polyneuropathy in as many as 50% of all patients is idiopathic. CSPN should be considered a distinct diagnostic subset of peripheral neuropathy. The onset of CSPN is predominantly in the sixth and seventh decades. Patients complain of distal numbness, tingling, and often burning pain that invariably begins in the feet and may eventually involve the fingers and hands. Patients exhibit a distal sensory loss to pinprick, touch, and vibration in the toes and feet, and occasionally in the fingers (Pattern 2; Table 438-2). It is uncommon to see significant proprioception deficits, even though patients may complain of gait unsteadiness. However, tandem gait may be abnormal in a minority of cases. Neither subjective nor objective evidence of weakness is a prominent feature. Most patients have evidence of both large- and small-fiber loss on neurologic examination and EDx. Approximately 10% of patients have only evidence of small-fiber involvement. The ankle muscle stretch reflex is frequently absent, but in cases with predominantly small-fiber loss, this may be preserved. The EDx findings range from isolated SNAP abnormalities (usually with loss of amplitude), to evidence for an axonal sensorimotor neuropathy, to a completely normal study (if primarily small fibers are involved). Therapy primarily involves the control of neuropathic pain (Table 438-6) if present. These drugs should not be used if the patient has only numbness and tingling but no pain.
Although no treatment is available that can reverse an idiopathic distal peripheral neuropathy, the prognosis is good. No benefit has been found with administration of intravenous immunoglobulin in patients with painful idiopathic small fiber neuropathy. Progression often does not occur or is minimal, with sensory symptoms and signs progressing proximally up to the knees and elbows. The disorder does not lead to significant motor disability over time. The relatively benign course of this disorder should be explained to patients.
CTS is a compression of the median nerve in the carpal tunnel at the wrist. The median nerve enters the hand through the carpal tunnel by coursing under the transverse carpal ligament. The symptoms of CTS consist of numbness and paresthesias variably in the thumb, index, middle, and half of the ring finger. At times, the paresthesias can include the entire hand and extend into the forearm or upper arm or can be isolated to one or two fingers. Pain is another common symptom and can be located in the hand and forearm and, at times, in the proximal arm. CTS is common and often misdiagnosed as thoracic outlet syndrome. The signs of CTS are decreased sensation in the median nerve distribution; reproduction of the sensation of tingling when a percussion hammer is tapped over the wrist (Tinel’s sign) or the wrist is flexed for 30–60 s (Phalen’s sign); and weakness of thumb opposition and abduction. EDx is extremely sensitive and shows slowing of sensory and, to a lesser extent, motor median potentials across the wrist. Ultrasound can show focal swelling of the median nerve at the wrist. Treatment options consist of avoidance of precipitating activities; control of underlying systemic-associated conditions if present; nonsteroidal anti-inflammatory medications; neutral (volar) position wrist splints, especially for night use; glucocorticoid/anesthetic injection into the carpal tunnel; and surgical decompression by dividing the transverse carpal ligament. The surgical option should be considered if there is a poor response to nonsurgical treatments; if there is thenar muscle atrophy and/or weakness; and if there are significant denervation potentials on EMG.
Other proximal median neuropathies are very uncommon and include the pronator teres syndrome and anterior interosseous neuropathy. These often occur as a partial form of brachial plexitis.
ULNAR NEUROPATHY AT THE ELBOW—“CUBITAL TUNNEL SYNDROME”
The ulnar nerve passes through the condylar groove between the medial epicondyle and the olecranon. Symptoms consist of paresthesias, tingling, and numbness in the medial hand and half of the fourth and the entire fifth fingers, pain at the elbow or forearm, and weakness. Signs consist of decreased sensation in an ulnar distribution, Tinel’s sign at the elbow, and weakness and atrophy of ulnar-innervated hand muscles. The Froment sign indicates thumb adductor weakness and consists of flexion of the thumb at the interphalangeal joint when attempting to oppose the thumb against the lateral border of the second digit. EDx may show slowing of ulnar motor NCV across the elbow with prolonged ulnar sensory latencies. Ultrasound can show swelling of the ulnar nerve around the elbow as well. Treatment consists of avoiding aggravating factors, using elbow pads, and surgery to decompress the nerve in the cubital tunnel. Ulnar neuropathies can also rarely occur at the wrist in the ulnar (Guyon) canal or in the hand, usually after trauma.
The radial nerve winds around the proximal humerus in the spiral groove and proceeds down the lateral arm and enters the forearm, dividing into the posterior interosseous nerve and superficial nerve. The symptoms and signs consist of wrist drop; finger extension weakness; thumb abduction weakness; and sensory loss in the dorsal web between the thumb and index finger. Triceps and brachioradialis strength is often normal, and triceps reflex is often intact. Most cases of radial neuropathy are transient compressive (neuropraxic) injuries that recover spontaneously in 6–8 weeks. If there has been prolonged compression and severe axonal damage, it may take several months to recover. Treatment consists of cock-up wrist and finger splints, avoiding further compression, and physical therapy to avoid flexion contracture. If there is no improvement in 2–3 weeks, an EDx study is recommended to confirm the clinical diagnosis and determine the degree of severity.
LATERAL FEMORAL CUTANEOUS NEUROPATHY (MERALGIA PARESTHETICA)
The lateral femoral cutaneous nerve arises from the upper lumbar plexus (spinal levels L2/3), crosses through the inguinal ligament near its attachment to the iliac bone, and supplies sensation to the anterior lateral thigh. The neuropathy affecting this nerve is also known as meralgia paresthetica. Symptoms and signs consist of paresthesias, numbness, and occasionally pain in the lateral thigh. Symptoms are increased by standing or walking and are relieved by sitting. There is normal strength, and knee reflexes are intact. The diagnosis is clinical, and further tests usually are not performed. EDx is only needed to rule out lumbar plexopathy, radiculopathy, or femoral neuropathy. If the symptoms and signs are classic, EMG is not necessary. Symptoms often resolve spontaneously over weeks or months, but the patient may be left with permanent numbness. Treatment consists of weight loss and avoiding tight belts. Analgesics in the form of a lidocaine patch, nonsteroidal agents, and occasionally medications for neuropathic pain can be used (Table 438-6). Rarely, locally injecting the nerve with an anesthetic can be tried. There is no role for surgery.
Femoral neuropathies can arise as complications of retroperitoneal hematoma, lithotomy positioning, hip arthroplasty or dislocation, iliac artery occlusion, femoral arterial procedures, infiltration by hematogenous malignancy, penetrating groin trauma, pelvic surgery including hysterectomy and renal transplantation, and diabetes (a partial form of lumbosacral diabetic plexopathy); some cases are idiopathic. Patients with femoral neuropathy have difficulty extending their knee and flexing the hip. Sensory symptoms occurring either on the anterior thigh and/or medial leg occur in only half of reported cases. A prominent painful component is the exception rather than the rule, may be delayed, and is often self-limited in nature. The quadriceps (patellar) reflex is diminished.
Sciatic neuropathies commonly complicate hip arthroplasty, pelvic procedures in which patients are placed in a prolonged lithotomy position, trauma, hematomas, tumor infiltration, and vasculitis. In addition, many sciatic neuropathies are idiopathic. Weakness may involve all motions of the ankles and toes as well as flexion of the leg at the knee; abduction and extension of the thigh at the hip are spared. Sensory loss occurs in the entire foot and the distal lateral leg. The ankle jerk and on occasion the internal hamstring reflex are diminished or more typically absent on the affected side. The peroneal subdivision of the sciatic nerve is typically involved disproportionately to the tibial counterpart. Thus, patients may have only ankle dorsiflexion and eversion weakness with sparing of knee flexion, ankle inversion, and plantar flexion; these features can lead to misdiagnosis of a common peroneal neuropathy.
The sciatic nerve divides at the distal femur into the tibial and peroneal nerve. The common peroneal nerve passes posterior and laterally around the fibular head, under the fibular tunnel. It then divides into the superficial peroneal nerve, which supplies the ankle evertor muscles and sensation over the anterolateral distal leg and dorsum of the foot, and the deep peroneal nerve, which supplies ankle dorsiflexors and toe extensor muscles and a small area of sensation dorsally in the area of the first and second toes.
Symptoms and signs consist of foot drop (ankle dorsiflexion, toe extension, and ankle eversion weakness) and variable sensory loss, which may involve the superficial and deep peroneal pattern. There is usually no pain. Onset may be on awakening in the morning. Peroneal neuropathy needs to be distinguished from L5 radiculopathy. In L5 radiculopathy, ankle invertors and evertors are weak and needle EMG reveals denervation. EDx can help localize the lesion. Peroneal motor conduction velocity shows slowing and amplitude drop across the fibular head. Management consists of rapid weight loss and avoiding leg crossing. Footdrop is treated with an ankle brace. A knee pad can be worn over the lateral knee to avoid further compression. Most cases spontaneously resolve over weeks or months.
Radiculopathies are most often due to compression from degenerative joint disease and herniated disks, but there are a number of unusual etiologies (Table 438-9). Degenerative spine disease affects a number of different structures, which narrow the diameter of the neural foramen or canal of the spinal column and compromise nerve root integrity; these are discussed in detail in Chap. 14.
TABLE 438-9Causes of Radiculopathy ||Download (.pdf) TABLE 438-9 Causes of Radiculopathy
Herniated nucleus pulposus
Degenerative joint disease
Vertebral body compression fracture
Compression by extradural mass (e.g., meningioma, metastatic tumor, hematoma, abscess)
Primary nerve tumor (e.g., neurofibroma, schwannoma, neurinoma)
Perineurial spread of tumor (e.g., prostate cancer)
Acute inflammatory demyelinating polyradiculopathy
Chronic inflammatory demyelinating polyradiculopathy
Infection (Lyme disease, herpes zoster, HIV, cytomegalovirus, syphilis, schistosomiasis, strongyloides)
Arachnoiditis (e.g., postsurgical)
The brachial plexus is composed of three trunks (upper, middle, and lower), with two divisions (anterior and posterior) per trunk (Fig. 438-2). Subsequently, the trunks divide into three cords (medial, lateral, and posterior), and from these arise the multiple terminal nerves innervating the arm. The anterior primary rami of C5 and C6 fuse to form the upper trunk; the anterior primary ramus of C7 continues as the middle trunk, while the anterior rami of C8 and T1 join to form the lower trunk. There are several disorders commonly associated with brachial plexopathy.
Brachial plexus anatomy. L, lateral; M, medial; P, posterior. (From J Goodgold: Anatomical Correlates of Clinical Electromyography. Baltimore, Williams and Wilkins, 1974, p. 56, with permission.)
Immune-Mediated Brachial Plexus Neuropathy
Immune-mediated brachial plexus neuropathy (IBPN) goes by various terms, including acute brachial plexitis, neuralgic amyotrophy, and Parsonage-Turner syndrome. IBPN usually presents with an acute onset of severe pain in the shoulder region. The intense pain usually lasts several days to a few weeks, but a dull ache can persist. Individuals who are affected may not appreciate weakness of the arm early in the course because the pain limits movement. However, as the pain dissipates, weakness and often sensory loss are appreciated. Attacks can occasionally recur.
Clinical findings are dependent on the distribution of involvement (e.g., specific trunk, divisions, cords, or terminal nerves). The most common pattern of IBPN involves the upper trunk or a single or multiple mononeuropathies primarily involving the suprascapular, long thoracic, or axillary nerves. Additionally, the phrenic and anterior interosseous nerves may be concomitantly affected. Any of these nerves may also be affected in isolation. EDx is useful to confirm and localize the site(s) of involvement. Empirical treatment of severe pain with glucocorticoids is often used in the acute period.
Brachial Plexopathies Associated with Neoplasms
Neoplasms involving the brachial plexus may be primary nerve tumors, local cancers expanding into the plexus (e.g., Pancoast lung tumor or lymphoma), and metastatic tumors. Primary brachial plexus tumors are less common than the secondary tumors and include schwannomas, neurinomas, and neurofibromas. Secondary tumors affecting the brachial plexus are more common and are always malignant. These may arise from local tumors, expanding into the plexus. For example, a Pancoast tumor of the upper lobe of the lung may invade or compress the lower trunk, whereas a primary lymphoma arising from the cervical or axillary lymph nodes may also infiltrate the plexus. Pancoast tumors typically present as an insidious onset of pain in the upper arm, sensory disturbance in the medial aspect of the forearm and hand, and weakness and atrophy of the intrinsic hand muscles along with an ipsilateral Horner’s syndrome. Chest computed tomography (CT) scans or magnetic resonance imaging (MRI) can demonstrate extension of the tumor into the plexus. Metastatic involvement of the brachial plexus may occur with spread of breast cancer into the axillary lymph nodes and local spread into the nearby nerves.
Perioperative Plexopathies (Median Sternotomy)
The most common surgical procedures associated with brachial plexopathy as a complication are those that involve median sternotomies (e.g., open-heart surgeries and thoracotomies). Brachial plexopathies occur in as many as 5% of patients following a median sternotomy and typically affect the lower trunk. Thus, individuals manifest with sensory disturbance affecting the medial aspect of forearm and hand along with weakness of the intrinsic hand muscles. The mechanism is related to the stretch of the lower trunk, so most individuals who are affected recover within a few months.
The lumbar plexus arises from the ventral primary rami of the first to the fourth lumbar spinal nerves (Fig. 438-3). These nerves pass downward and laterally from the vertebral column within the psoas major muscle. The femoral nerve derives from the dorsal branches of the second to the fourth lumbar ventral rami. The obturator nerve arises from the ventral branches of the same lumbar rami. The lumbar plexus communicates with the sacral plexus by the lumbosacral trunk, which contains some fibers from the fourth and all of the fibers from the fifth lumbar ventral rami (Fig. 438-4).
Lumbosacral plexus. (From AA Amato, JA Russell (eds): Neuromuscular Disorders, 2nd ed. McGraw-Hill Education, 2016, Table 24-3, p. 541, with permission.)
Lumbosacral trunk sacral plexus, and sciatic nerve. (From AA Amato, JA Russell (eds): Neuromuscular Disorders, 2nd ed. McGraw-Hill Education, 2016, Table 24-4, p. 542, with permission.)
The sacral plexus is the part of the lumbosacral plexus that is formed by the union of the lumbosacral trunk with the ventral rami of the first to fourth sacral nerves. The plexus lies on the posterior and posterolateral wall of the pelvis with its components converging toward the sciatic notch. The lateral trunk of the sciatic nerve (which forms the common peroneal nerve) arises from the union of the dorsal branches of the lumbosacral trunk (L4, L5) and the dorsal branches of the S1 and S2 spinal nerve ventral rami. The medial trunk of the sciatic nerve (which forms the tibial nerve) derives from the ventral branches of the same ventral rami (L4-S2).
Plexopathies are typically recognized when motor, sensory, and if applicable, reflex deficits occur in multiple nerve and segmental distributions confined to one extremity. If localization within the lumbosacral plexus can be accomplished, designation as a lumbar plexopathy, a sacral plexopathy, a lumbosacral trunk lesion, or a pan-plexopathy is the best localization that can be expected. Although lumbar plexopathies may be bilateral, usually occurring in a stepwise and chronologically dissociated manner, sacral plexopathies are more likely to behave in this manner due to their closer anatomic proximity. The differential diagnosis of plexopathy includes disorders of the conus medullaris and cauda equina (polyradiculopathy). If there is a paucity of pain and sensory involvement, motor neuron disease should be considered as well.
The causes of lumbosacral plexopathies are listed in Table 438-10. Diabetic radiculopathy (discussed above) is a fairly common cause of painful leg weakness. Lumbosacral plexopathies are a well-recognized complication of retroperitoneal hemorrhage. Various primary and metastatic malignancies can affect the lumbosacral plexus as well; these include carcinoma of the cervix, endometrium, and ovary; osteosarcoma; testicular cancer; MM; lymphoma; acute myelogenous leukemia; colon cancer; squamous cell carcinoma of the rectum; adenocarcinoma of unknown origin; and intraneural spread of prostate cancer.
TABLE 438-10Lumbosacral Plexopathies: Etiologies
RECURRENT NEOPLASTIC DISEASE OR RADIATION-INDUCED PLEXOPATHY
The treatment for various malignancies is often radiation therapy, the field of which may include parts of the brachial plexus. It can be difficult in such situations to determine if a new brachial or lumbosacral plexopathy is related to tumor within the plexus or from radiation-induced nerve damage. Radiation can be associated with microvascular abnormalities and fibrosis of surrounding tissues, which can damage the axons and the Schwann cells. Radiation-induced plexopathy can develop months or years following therapy and is dose dependent.
Tumor invasion is usually painful and more commonly affects the lower trunk, whereas radiation injury is often painless and affects the upper trunk. Imaging studies such as MRI and CT scans are useful but can be misleading, especially when there is small microscopic invasion of the plexus. EMG can be informative if myokymic discharges are appreciated, as this finding strongly suggests radiation-induced damage.
EVALUATION AND TREATMENT OF PLEXOPATHIES
Most patients with plexopathies will undergo both imaging with MRI and EDx evaluations. Severe pain from acute idiopathic lumbosacral plexopathy may respond to a short course of glucocorticoids.
AA, Russell J: Neuromuscular Disorders, 2nd ed. New York, McGraw-Hill, 2016.
B: Entrapment neuropathies. Neurol Clin 31:405, 2013.
AA. Pattern-recognition approach to neuropathy and neuronopathy. Neurol Clin 31:343, 2013.
et al: Evaluation of distal symmetric polyneuropathy: The role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Muscle Nerve 39:106, 2009.
et al: Evaluation of distal symmetric polyneuropathy: The role of laboratory and genetic testing (an evidence-based review). Muscle Nerve 39:116, 2009.
et al: Inherited neuropathies: Clinical overview and update. Muscle Nerve 48:604, 2013.
et al: Diabetic neuropathy part 1: Overview and symmetric phenotypes. Neurol Clin 31:425, 2013.
et al: Diabetic neuropathy part 2: Proximal and asymmetric phenotypes. Neurol Clin 31:447, 2013.
et al: Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol 69:22, 2011.
et al: Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: A systematic review. Neurology 87:978, 2016.
Additional Online Reference
et al: Intravenous Immunoglobulin therapy in patients with painful idiopathic small fiber neuropathy. Neurology 96:e2534, 2021.
et al: Effect of high-frequency (10-kHz) spinal cord stimulation in patients with painful diabetic neuropathy: A randomized clinical trial. JAMA Neurol, 2021 [Epub ahead of print].
et al: Novel autoantibodies in idiopathic small fiber neuropathy. Ann Neurol 91:66, 2022.